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ABSTRACT 
Background: As many as 32.5% of individuals experiencing neuropsychological decline 
display some form of visual impairment as part of their disease aetiology, and extensive 
research supports the inclusion of tests of visual perception in wider neuropsychological 
assessment to determine whether an individual is displaying symptoms of dementia. 
However, less is known about the extent to which these tests can help differentiate 
between different types of dementia. Aims: The current review examined the extent to 
which tests of visual perception can help to differentiate between different types of 
dementia. In addition, the review aimed to evaluate the methodological quality and risk 
of bias of included studies. Methods: Three research databases were searched for 
studies which satisfied the inclusion and exclusion criteria. Data from relevant studies 
were extracted and results synthesised. Included studies were reviewed for risk of bias 
and methodological quality using the QUADAS-2 and STARD guidelines. Results: 
Fourteen studies were included in the review. A low risk of bias was observed in relation 
to index test and reference standard, and there were few concerns regarding the 
applicability and clinical utility of results. A high risk of bias was identified regarding 
patient selection, and STARD ratings for methodological quality ranged from 25–38. 
Evidence was provided to support the finding that tests of visual perception can 
differentiate between Alzheimer’s Disease and other types of dementia. In particular, 
those with Alzheimer’s Disease typically outperform those who have Dementia with Lewy 
Bodies on these tests, but perform worse than those with Frontotemporal Dementia. 
Conclusion: There is evidence that tests of visual perception can aid differential 
diagnosis in dementia. However, improvements in the quality of research in this area is 
needed as well as greater understanding of the diagnostic accuracy of these tests. 




Visual impairment is a common problem for people with a diagnosis of dementia. This 
can include impairments in visual acuity, experienced by as many as 32.5% of dementia 
patients (Bowen et al, 2016), or with visual perception functions such as visuo-spatial 
processing, cited by Geldmecher (2003) as the most common form of visual impairment 
in dementia. 
Several tests commonly used to assess neurocognitive ability include measures of visual 
processing, including the Addenbrookes Cognitive Examination (Hsieh et al, 2013), the 
Repeatable Battery for the Assessment of Neuropsychological Status (Randolph et al, 
1998) and the Severe Impairment Battery (Saxton et al, 1990). However, there remains 
overlap between the different visual processes required for these tests, for example 
between visuo-spatial function, defined by Simic et al. (2013) as “processes involved in 
perceiving spatial location, orientation, direction and distance” (p1119), and visuo-
constructional ability, defined as “skills needed to put together parts to form a single 
whole” (Simic et al. (2013; p 1119)). 
The ‘type’ of neurocognitive decline can have distinct effects on visual perception. 
Although Alzheimer’s Disease and Dementia with Lewy Bodies can both lead to 
impairments in visual processing, memory impairments are often the first noticeable 
symptoms in Alzheimer’s Disease (Gottesman and Stern, 2019). During the early stages 
of disease onset however, individuals with Dementia with Lewy Bodies are reported to 
experience more severe visual impairments as part of their disease aetiology than those 
with Alzheimer’s Disease (McKeith et al, 2017), and these visual impairments are more 
likely to include visual hallucinations and visual perception difficulties (Rosenblum et al, 
2021). However, Dementia with Lewy Bodies is often misdiagnosed as Alzheimer’s 
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Disease due to overlapping symptoms including problems with memory and language 
(Thomas et al, 2018). 
Misdiagnosis of the specific dementia type an individual is experiencing can lead to the 
inappropriate treatment and management of symptoms, as well as inaccuracies relating 
to prognosis. Thorough assessment and accurate diagnosis of dementia type is, 
therefore, essential for providing appropriate post-diagnostic support, and visual 
assessment has been proposed as one method for improving clinical judgement in this 
area (Possin, K.L., 2011). 
Aims 
The current review aimed to examine the extent to which tests of visual perception can 
help to differentiate between different types of dementia. In addition, the review aimed 
to evaluate the methodological quality and risk of bias of included studies. 
METHODS
The review adhered to the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) statement (Page et al., 2021), and the following sections outline the 
review protocol. 
Search Strategy 
The Ovid platform was used to search EMBASE, Medline and APA PsychINFO 
databases for relevant studies. The international database of prospectively registered 
systematic reviews (PROSPERO; University of York, 2019) was also checked to 
determine if there were any similar reviews in progress. The ‘PICO’ framework was 
utilised to help focus the search strategy, as outlined below: 
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Population: The inclusion criteria included studies involving adults (i.e., those aged 18 
and over) with a confirmed diagnosis of dementia. Studies involving participants with 
unconfirmed or undiagnosed dementia were excluded. 
Intervention: The studies included did not involve direct intervention. Rather, 
performance on tests of visual perception included within commonly used 
neuropsychological assessments were reviewed. 
Comparison The inclusion criteria involved studies which aimed to identify scores on 
tests of visual perception and compare those obtained by individuals with different types 
of dementia (i.e., comparison of performance between at least two distinct dementia 
groups). Studies which aimed to utilise tests of visual perception to differentiate between 
individuals with dementia and individuals without dementia, or with individuals with other 
neurocognitive disorders (e.g., Huntington’s Disease, Alcohol Related Brain Damage) in 
the absence of a diagnosis of dementia, were omitted by the exclusion criteria. 
Outcome: The review aimed to evaluate the methodological quality of studies which 
used tests of visual perception to differentiate between different types of dementia. The 
outcome measure of interest for these studies therefore included visual perception 
ability, which was assessed using various different neuropsychological assessment 
tools, as outlined above. To satisfy the inclusion criteria, only studies which reported 
results of tests of visual perception were included. Qualitative studies, and studies not 
published in English, were excluded from the review. 
EMBASE, Medline and APA PsycINFO were searched to identify articles which included 
the following terms in either Abstract, Keyword or Title: 
(Dementia) AND (Differenti* OR Distin*) AND (Visu*) 
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These search terms were determined after scoping searches indicated that they were 
commonly used in studies comparing performance on tests of visual perception between 
different forms of dementia. No limit regarding publication date was set. After the search 
was conducted and the initial studies were identified, duplicates were removed and the 
remainder were screened for appropriateness using titles and abstracts. The remaining 
full text articles were then examined, and reference lists of included studies were also 
reviewed to identify any additional studies of relevance. 
An independent rater replicated this search and, following the removal of duplicates, 
repeated the above process for 10% (n=211) of the total search results in order to 
determine inter-rater reliability. The independent rater identified all three studies included 
by the investigator in the sample, in addition to three studies which had been excluded 
by the investigator, resulting in ‘substantial’ (k=0.66) agreement. Agreement was 
reached to exclude the three additional studies as two did not measure visual perception, 
and one did not compare groups with a confirmed diagnosis of dementia. 
Methodological Quality 
Included studies were assessed for risk of bias using the Quality Assessment of 
Diagnostic Accuracy Studies 2 (QUADAS-2; Whiting et al, 2011). The QUADAS-2 
includes 18 questions and was developed to assess risk of bias and concerns about 
applicability in studies related to diagnostic accuracy. Risk of bias and concerns about 
applicability are rated across three domains; patient selection, index test and reference 
standard. A fourth domain, flow and timing, is also rated for risk of bias. Domain-specific 
signalling questions are also provided for each domain, for example ‘Was a consecutive 
or random sample of patients enrolled?’. Potential responses indicating low risk of bias 
include ‘Yes’ and ‘Low’, whereas ‘No’ and ‘High’ indicate a high risk of bias for that 
particular item. Concerns Regarding Applicability are rated as either ‘Low’ or ‘High’. For 
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both risk of bias and concerns about applicability, items can be rated ‘Unclear’ if there is 
insufficient evidence for rating. 
Unlike many risk of bias tools the QUADAS-2 emphasises that overall or mean numeric 
scores should not be generated to summarise a study. Instead, studies receiving a rating 
of ‘High’, ‘No’ or ‘Unclear’ on one or more items within a domain should be considered 
to be ‘at risk of bias’ or presenting ‘concerns regarding applicability’ within that domain. 
The signalling questions, including potential responses, for each domain are outlined in 
Appendix 1.2. 
Included studies were also assessed for reporting quality using the ‘Standards for 
Reporting Diagnostic accuracy studies’ (STARD; Bossuyt et al, 2015). The STARD 
includes 31 items aimed at providing international consensus guidelines for assessing 
the reporting quality of studies investigating diagnostic accuracy. Prompt questions are 
provided which relate to six domains including, Title and Abstract, Introduction, Methods 
(including Study Design, Participants, Test Methods, Analysis), Results (including 
Participants and Test Results) and Discussion (Appendix 1.3). Each item is rated either 
0 (information missing), 1 (some information present but insufficient detail) or 2 
(information present) to provide an overall score out of 62. 
An independent rater assessed 50% of the included studies using the QAUDAS-2 and 
STARD in order to determine whether assessment scores were reliable. This resulted in 
‘substantial (k=.74) and ‘almost perfect’ (k =.81) agreement between the raters for 
QUADAS-2 and STARD ratings, respectively. Discrepancies in scoring were discussed 
in order that consensus could be reached. 
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RESULTS
Outcome of Search Process 
The search process identified 3535 initial studies. As the PRISMA 2020 (Page et al., 
2021) flow diagram in Figure 1 illustrates, this included 1425 duplicate studies. The titles 
and abstracts of the remaining 2110 studies were reviewed, and application of the 
selection criteria resulted in the exclusion of a further 2072 studies. The full text of 38 
remaining studies were screened for eligibility, of which 13 were excluded as they did 
not include measurement of visual perception. Dementia diagnosis was not confirmed 
for 4 additional studies, and 8 studies did not include a comparison between different 
dementia types. References listed in each of the 13 remaining papers were examined, 
and 1 additional study satisfying the selection criteria was subsequently identified. 
Figure 1: PRISMA 2020 flow diagram for systematic reviews 
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Study Characteristics 
The fourteen studies included in the review were examined for participant information 
and test characteristics. Table 1 outlines data relating to dementia types and sample 
size, gender, age and education of participants included in each study along with the 
tests used and the results and outcome of each study. 
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Mean score (SD) 




M. A. et al.
(2020)





Mioshi et al, 2006): 
Visuo-spatial test 
10.2 (3.9) 
No sig diff. between 
DLB & AD on VS sub-
test; 





AD (40) 28:12 73.8 (8.6) 12.5 (2.9) 12.3 (3.4) 
HC (66) 42:24 72.6 (6.9) 14.1 (3.4) 15.6 (0.8) 
Pouzeta, A. et 
al. (2019) 
AD (32) 9:23 66.4 (5.9) 10.5 (3.3) 








scores for AD group 
compared with SD 
group (p=.015) 
bvFTD (20) 15:5 72.7 (7.3) 10.6 (5.5) 6.63 (3.28) 
SD (35) 18:17 71.3 (8.4) 9.6 (3.1) 7.67 (2.88) 
Salimi, S. et al. 
(2019) 
AD (55) 31:24 65.0 (8.1) 12 (3.1) 
a) ACE-R/ACE-III











Scores for AD group 
were significantly lower 
than those for bvFTD 
group on ACE-R/ACE-
III (F(1, 95)=5.2, 
p=0.025) and RCF 
(F(1, 93)=4.8, p=0.031) 






c1) VOSP: Dot 
Counting 
c2) VOSP: Position 
Discrimination 
c3) VOSP: Cube 
Analysis 
c3) 8.3 (0.5) 






Scharre, D.W. et 
al. (2016) 
AD (21) 13:8 75.1 (5.0) 14.7 (2.1) 


















DLB group performed 
significantly worse on 
MMSE Pentagon Copy 
task (p=.0126) and 




DLB (21) 13:8 74.0 (4.8) 15.6 (2.6) 
a) Correctly
copied by 23.8 %
of group
b) 1.29 (1.31)





Park, L.Q. et al. 
(2015) 









(ECog: Farias et al., 
2008): Visuo-spatial 
sub-test 
2.87 (0.96) AD group significantly 
more impaired on task 
than FTD group (β=-
0.34, SE=0.13, p=.01) FTD (13) 71.2 (11.4) 13.6 (3.2) 2.20 (0.96) 
Giovagnoli, A.R. 
et al. (2008) 





AD group significantly 
more impaired on RCF 
(F(2, 165)=154.79, 
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between groups on 
Raven’s test not 
significant 
HC (91) 41:50 62.3 (10.0) 11.3 (4.4) 
a) 31.27 (4.71)
b) 32.87 (2.93)
Kandiah, N. et 
al. (2009) 
AD (78) 41:37 72.0 (8) 














a) 30.2 (SD not
specified)
b) 3.45 (SD not
specified)
c) 12.2 (SD not
specified)
AD group performed 
significantly better than 
SIVD group on all tests 





SIVD (78) 54:24 70.0 (9) 
4.5 (SD not 
specified) 
a) 23.4 (SD not
specified)
b) 2.73 (SD not
specified)
c) 6.80 (SD not
specified)
Charles, R.F & 
Hillis, A.H. 
(2005) 










AD group performed 
significantly better than 
PCA group on 
CORVIST (p<.001) and 




Tiraboschi, P. et 
al. (2006) 














AD group performed 
significantly better than 
DLB group on 
Dementia Rating Scale 
– Construction
subscale;
Odds ratio (95% C.I.) =
3.5 (1.3-9.7); No
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DLB (23) 13:10 73.7 (4.8) 14.7 (2.8) 








significant difference in 
scores on MMSE 
(p=.1) 
Graham, N.L. et 
al. (2003) 
AD (19) 9:10 68.9 (8.6) 13.1 (3.4) 
a) RCF Copy
b1) VOSP: Letters 
b2) VOSP: 
Silhouette 
b3) VOSP: Object 
Decision 
b4) VOSP: Dot 
Counting 
b5) VOSP: Number 
Location 









AD group performed 
significantly better than 
VD group on VOSP 
Silhouette task (Wald’s 
X2(1)=4.58, p<.05, 
odds ratio = 1.18); No 
significant difference in 
scores on remaining 
VOSP tasks or RCF 
Copy 
















Ala, T.A. et al. 
(2001) 




by 59% of group 
AD group performed 
significantly better than 
DLB group (Fisher’s 
exact test, p=.002); 
failure on task 
associated with DLB 
with sensitivity of 88% 
DLB (17) 11:6 75.0 (7.2) 13.6 (3.3) 
Correctly copied 
by 12% of group 
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(95% CI, 0.64-0.99), 
specificity of 59% (95% 
CI, 0.39-0.78) 
Elfgren, C. et al. 
(1994) 
AD (17) 6:11 
66.0 (SD not 
specified) 
Not specified 
Block Design Test 
(Wechsler, 1958) 
Median score = 
0/24 
AD group performed 
significantly worse on 
Block Design Test than 
FTD group (Stanine 
scale scores = 2, 3, 
p=.003) 
FTD (11) 4:7 
58.0 (SD not 
specified) 
Not specified 
Median score = 
13/24 
Yamamoto, E. et 
al. (2017) 




1.91 (0.81) AD group performed 
significantly better than 
DLB group (p<.001; 
D=0.58) DLB (73) 42:31 73.3 (7.3) Not specified 1.40 (0.88) 
Gnanalingham, 
K.K et al. (1997) 
AD (25) 12:13 75.7 (1.4) 9.9 (0.4) 
a1) Clock face test: 
Draw part 
a2) Clock face test: 
Copy part 
(Libon et al, 1993) 
a1) 3.7 (0.5) 
a2) 5.5 (0.7) 
AD group performed 
significantly better than 
DLB group on Draw 
part (p<.01)* and Copy 
part (p<.01)* of Clock 
face test 
 
*Statistical value not 
reported 
DLB (16) 8:8 76.4 (1.8) 11.0 (1.1) 
a1) 2.4 (0.4) 
a2) 2.4 (0.6) 
PD (15) 10:5 72.6 (2.1) 10.3 (0.9) 
a1) 6.2 (0.7) 
a2) 7.1 (0.8) 
HC (22) 13:9 73.3 (1.3) 10.1 (0.5) 
a1) 8.2 (0.2) 
a2) 9.6 (0.1) 
 
Abbreviations: AD (Alzheimer’s Disease); bvFTD (Behavioural Variant Frontotemporal Dementia); DLB (Dementia with Lewy Bodies); FTD (Frontotemporal 
Dementia); HC (Healthy Controls); PCA (Posterior Cortical Atrophy); PD (Parkinson’s Disease); SD (Semantic Dementia); SIVD (Subcortical Ischemic Vascular 
Dementia); VD (Vascular Dementia) 
*M:F ratio as reported in study      **Total CORVIST scores (individual sub-test scores not reported)
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As Table 2 outlines, the fourteen studies included 1,577 participants across 34 different 
groups. This involved five different dementia groups, and five studies also included a ‘healthy 
control’ (i.e., non-dementia) group. All studies included an Alzheimer’s Disease group, and the 
majority of overall participants (N=797, 51.2%) had this diagnosis. 
Table 2: Aggregated patient characteristics by dementia type and overall 
Dementia Type 
N Groups 
(% of total) 
N 
Participants 
(% of total) 





14 (41.2) 797 (51.2) 241:239** 73.3 12.0*** 
Dementia with 
Lewy Bodies 
6 (17.6) 226 (14.5) 151:75 74.3 12.9** 
Frontotemporal 
Dementia**** 
6 (17.6) 170 (10.9) 83:87 65.4 10.6*** 
Healthy Controls 5 (14.7) 252 (16.2) 147:105 67.6 11.6  
Posterior Cortical 
Atrophy 
1 (2.9) 15 (1.0) 4:11 65.3 (Not reported) 
Vascular 
Dementia***** 
2 (5.9) 97 (6.2) 68:29 70.2  5.9 
Total 34 1557 675:512** 71.4  11.5*** 
* Means reported are pooled means based on ‘Dementia Type’ groups
** Excludes data from studies which did not report gender ratio (Park, L.Q. et al. (2015); Giovagnoli,
A.R. et al. (2008))
*** Excludes data from studies which did not report Mean (Elfgren, C. et al. (1994); Charles, R.F & Hillis,
A.H. (2005); Yamamoto, E. et al. (2017))
****Includes Behavioural Variant Frontotemporal Dementia group (Pouzeta et al., 2019; Salimi et al.,
2019) and Semantic Dementia group (Pouzeta et al., 2019)




Risk of Bias – QUADAS-2 
The outcome of the QUADAS-2 risk of bias and concerns regarding applicability assessment 
for each study is detailed in Table 3, and individual ratings for each study are presented in 
Appendix 1.2.  
 
Table 3: Outcome of QUADAS-2 risk of bias assessment 
Study 
















et al., 2020 
H L L Unclear L L L 
Pouzeta, A. et 
al., 2019 
H L L H L L L 
Salimi, S. et 
al., 2019 
H L L H L L L 
Scharre, D.W. 
et al., 2016 
H Unclear H Unclear L L L 
Park, L.Q. et 
al., 2015 
H L L H L L L 
Giovagnoli, 
A.R. et al, 
2008 
H L L Unclear L Unclear Unclear 
Kandiah, N. et 
al., 2009 
H L L Unclear L L L 
Charles, R.F & 
Hillis, A.H., 
2005 
H L L Unclear L L L 
Tiraboschi, P. 
et al., 2006 
H Unclear H Unclear L Unclear L 
Graham, N.L. 
et al., 2003 
H L L Unclear L L L 
Ala, T.A. et al., 
2001 
H L L Unclear H L Unclear 
Elfgren, C. et 
al., 1994 
H Unclear H Unclear L Unclear L 
Yamamoto, E. 
et al., 2017 
H H H Unclear L Unclear L 
Gnanalingham, 
K.K. et al, 
1997 
H L L Unclear L L L 
*Shaded boxes indicate High/Unclear risk of bias/Concerns regarding applicability 
 
As Table 3 highlights, all studies displayed a high risk of bias for patient selection. This was 
due to each study utilising a case control design, whereby participants were assigned to 
groups based on pre-determined dementia diagnoses. Considering the aims and hypotheses 
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of the studies involved however, it would have been difficult to apply a non-observational study 
design. However, studies involving recruitment based on consecutive referrals could have 
limited the risk of bias regarding patient selection.   
 
The majority of studies displayed a low risk of bias in relation to index test and reference 
standard. For most (N=11) studies the results of the index test(s) were interpreted without 
knowledge of the relevant reference standards. Similarly, for most (N=13) studies there was 
a low risk of bias regarding the interpretation of the reference standard, and prior dementia 
diagnoses had been informed by thorough neuropsychological assessment across various 
cognitive domains. However, risk of bias relating to the flow of participants through the studies 
was difficult to assess due to limited or unclear information regarding how missing and 
indeterminate data were addressed.  
 
As Figure 2 highlights however, overall there were minimal concerns regarding the applicability 
of results. Most studies sufficiently outlined the clinical implications of their findings, although 
some (Tiraboschi et al., 2006; Elfgren et al., 1994; Yamamoto et al., 2017) did not 
comprehensively relate these to the review question.  
 
Risk of Bias 
Flow and Timing High (3) Unclear (11) 
Patient Selection High (14) 
Index Test Low (11) Unclear (3) 
Reference Standard Low (10) High (4) 
Concerns Regarding Applicability 
Patient Selection Low (13) H. (1) 
Index Test Low (10) Unclear (4) 
Reference Standard Low (12) Unclear (2) 
 
Figure 2: Proportion of studies displaying Low, High and Unclear risk of bias and concerns 
regarding applicability 






Reporting Quality Assessment: STARD 
Individual STARD ratings for each study are presented in Appendix 1.4, and as Table 4 
outlines overall STARD ratings ranged from 25 to 38. The mean overall STARD score was 
33.4. Similar common issues to those identified within the QUADAS-2 were noted, including 
inadequate descriptions of missing and indeterminate data, and of the flow of participants 
through the study. Also, all studies failed to adequately justify sample size, and most offered 
insufficient detail on setting, location and dates relating to data collection.  
 
Table 4: STARD quality assessment outcomes 
 
However, most studies provided an appropriate and detailed summary of study design, 
methods, results and conclusions as well as a thorough scientific and clinical background to 
the relevant index test(s). The methods for estimating or comparing measures of diagnostic 
accuracy were described well overall, with cross tabulation of results and participant 
demographics generally well presented.  
 
Synthesis of Results by Test(s) Used 
The main findings for each study are presented in Table 5 (below). Of the eighteen different 
tests used, five were included in more than one study: ACE-R/ACE-III Visuo-spatial sub-test; 
MOCA Clock Drawing/Clock Face Test (Draw); MMSE Pentagon Copy; RCF; VOSP (Number 
Study STARD Score Study STARD Score 
Prats-Sedano et al.  
(2020) 
35 
Charles and Hillis 
(2005) 
34 
Pouzeta et al. (2019) 35 
Tiraboschi et al. 
(2006) 
34 
Salimi et al. (2019) 38 Graham et al. (2003) 36 
Scharre et al. (2016) 33 Ala et al. (2001) 28 
Park et al. (2015) 37 Elfgren et al. (1994) 25 
Giovagnoli et al. 
(2008) 
33 
Yamamoto et al. 
(2017) 
30 
Kandiah et al. (2009) 34 




Location). Tests which have been used to compare at least two different dementia types, and 
where those disease comparisons have been replicated in more than one study, have been 
synthesised below. 
Table 5: Tests and dementia types included in studies 
Test AD DLB FTD HC PCA VD 
ACE-R/ACE III: V-S 
Prats-S. Prats-S. Prats-S. 
Salimi Salimi Salimi 
Block Design Test Elfgren Elfgren 
Clock Test: Copy Gnana. Gnana. Gnana. 
MOCA Clock Drawing/ 
Clock Test: Draw 
Gnana. Gnana. Gnana. 
Kandiah Kandiah 
Yamamoto Yamamoto 
CORVIST Charles Charles 
DRS: Construction Tiraboschi Tiraboschi 





Ravens Progressive M. Giovagnoli Giovagnoli Giovagnoli 
RCF: Copy 
Giovagnoli Giovagnoli Giovagnoli 
Charles Charles 
Graham Graham Graham 
SAGE: Visuo-Spatial Scharre Scharre 
VOSP: Cube Analysis Graham Graham Graham 
VOSP: Dot Counting Graham Graham Graham 
VOSP: Incomplete L. Graham Graham Graham 
VOSP: Number Location 
Pouzeta Pouzeta 
Graham Graham Graham 
VOSP: Object D. Graham Graham Graham 
VOSP: Silhouettes Graham Graham Graham 
WMS-R: Visual Rep. Kandiah Kandiah 
Abbreviations: AD (Alzheimer’s Disease); DLB (Dementia with Lewy Bodies); FTD (Frontotemporal 
Dementia); HC (Healthy Controls); PCA (Posterior Cortical Atrophy); VD (Vascular Dementia); 
*Tests in shaded boxes used in more than one study
ACE-R/ACE-III Visuo-spatial sub-test 
The Visuo-spatial sub-test of the second and third versions of the Addenbrookes Cognitive 
Examination (ACE-R; ACE-III) were included in studies by Prats-Sedano et al. and Salimi et 
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al. As Salimi et al. identify, there is a high correlation between these tests, with the only 
difference relating to the drawing of interlocking infinity diagrams in the ACE-III as opposed to 
interlocking pentagons in the ACE-R. A study by So et al. (2018) found no significant difference 
in visuo-spatial scores between test versions (Z=-.895, p=.371; So, M. et al, 2018). 
Prats-Sedano et al. found that individuals with Alzheimer’s Disease (M=12.3, SD=3.4) 
performed significantly better than those who had Dementia with Lewy Bodies (M=10.2, 
SD=3.9; U=1041.5, p=.005). However, Salimi et al. found that those with Alzheimer’s 
Dementia performed significantly worse (M=12.8, SD=.4) than those with Frontotemporal 
Dementia (M=14.1, SD=.4; F(1, 95)=5.2, p=.025). It was not possible to statistically combine 
the results of these studies however as they did not compare ACE-R/ACE-III Visuo-spatial 
scores between similar disease groups. 
MOCA Clock Drawing /Clock Face Test (Draw) 
The clock drawing tasks in Gnanalingham et al., Kandiah et al. and Yamamoto et al.’s studies 
involved drawing an analogue clock face and placing the hands at ‘ten minutes after eleven 
o’clock’. Kandiah et al. found that individuals with Alzheimer’s Disease obtained a mean score 
of 3.45 (SD not reported), whereas those with Subcortical Ischemic Vascular Dementia 
performed worse with a mean score of 2.73 (SD not reported). This difference was found to 
be significant (p=.018). 
Gnanalingham et al. and Yamamoto et al. both found significant differences between the 
performances of individuals with Alzheimer’s Disease and Dementia with Lewy Bodies. In 
Gnanalingham et al.’s study participants with Alzheimer’s Disease performed better (M=3.7, 
SD=.5) than those with Dementia with Lewy Bodies (M=2.54, SD=.4; p<.01). Similarly, 
Yamamoto et al. reported a higher mean score for those with AD (M=1.91, SD=.81) than those 
with Dementia with Lewy Bodies (M=1.4, SD=.88; t(128)=.58, p<.001). Unfortunately, as 
Gnanalingham et al. did not report a statistical value or effect size, and Yamamoto et al. did 
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not report a precise p value, it was not possible to synthesise the results of these studies. As 
the results of the QUADAS-2 highlight however Yamamoto et al.’s study displayed a high risk 
of bias in relation to index test and reference standard, meaning that any synthesis of results 
between these studies would perhaps offer limited clinical or theoretical value. 
 
MMSE Pentagon Copy 
The Pentagon Copy task within the MMSE was included in studies by Scharre et al., Ala et al. 
and Tiraboschi et al. to compare between individuals with Alzheimer’s Disease and those with 
Dementia with Lewy Bodies. In all studies, a higher percentage of individuals in the 
Alzheimer’s Disease groups produced correct copies of the pentagon (66.7%, 59.3%, 84.0%) 
than in the Dementia with Lewy Bodies groups (23.8%, 11.8% and 70%). Scharre et al. and 
Ala et al. found these differences to be significant (p=.0126; p=.002), with Tiraboschi et al. 
obtaining results approaching significance (p=.10). Ala et al. and Tiraboschi et al. reported 
sensitivities of 88% (95% C.I., .64-.99) and 30%, and specificities of 59% (95% C.I., .39-.78) 
and 84%, respectively, regarding the use of failure on the pentagon to discriminate between 
Alzheimer’s Disease and Dementia with Lewy Bodies.  
 
Combining the results of the three studies indicate an overall mean of 76.7% and 37.9% 
correctly copied pentagons in the Alzheimer’s Disease and Dementia with Lewy Bodies 
groups, respectively.  
 
Synthesis of Results by Dementia Type 
There were five different dementia types included across the fourteen studies, and all studies 
involved a comparison between Alzheimer’s Disease and another disease type. As Table 6 
outlines, there were 27 overall between-group comparisons between Alzheimer’s Disease 
groups and other disease types. These comparisons included 19 different tests of visual 
perception. In all comparisons, Alzheimer’s Disease groups performed better than Dementia 
with Lewy Bodies (N=9), Vascular Dementia (N=10) and Posterior Cortical Atrophy (N=2) 
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groups across 16 different tests of visual processing. All of these results were significant, with 
the exception of the MMSE Pentagon task within Tiraboschi et al.’s study.  
 
Although the Alzheimer’s Disease groups outperformed Dementia with Lewy Bodies groups 
in six different studies, and Vascular Dementia groups in two different studies, this effect was 
observed in a comparison against Posterior Cortical Atrophy in a single study only. This study, 
by Charles and Hillis, demonstrated a high risk of bias regarding patient selection, but low risk 
of bias relating to index test and reference standard, and low concerns regarding applicability 
in these areas. When compared with Frontotemporal Dementia however, Alzheimer’s Disease 
groups performed worse in each of the six measures used, and only Pouzeta et al.’s study 
failed to find a significant effect for this difference.  
  
Table 6: Performance of Alzheimer Disease groups compared with other dementia types on 
tests of visual perception 
 
AD>Dementia with Lewy Bodies AD>Vascular Dementia 
Study Test p Study Test p 
Prats-S. et al. ACE-R/III Visuo-sp. .005 Graham et al. RCF: Copy <.001 
Scharre et al. MMSE Pentagon .0161 Graham et al. VOSP Incomplete L. N.S. 
Scharre et al. SAGE .0126 Graham et al. VOSP Silhouettes <.001 
Tiraboschi et al. DRS-Construction .011 Graham et al. VOSP Object Disc. N.S. 
Tiraboschi et al.. MMSE Pentagon .1 Graham et al. VOSP Dot Counting <.05 
Ala et al. MMSE Pentagon .002 Graham et al. VOSP Number Loc. N.S. 
Gnana. et al. Clock Draw <.001 Graham et al. VOSP Cube Analysis <.01 
Yamomoto et al. Clock Draw <.01 Kandiah et al. WMS-R V-R .005 
Yamamoto et al. Clock Copy <.01 
Kandiah et al. Clock Draw .018 
Kandiah et al. Block Design .001 
AD>Posterior Cortical Atrophy 
Study Test p Study Test p 
Charles and Hills CORVIST <.001 Charles and Hills RCF: Copy <.001 
AD<Frontotemporal Dementia 
Study Test p Study Test p 
Giovagnoli et al. Raven’s P.M. <.001 Pouzeta et al. VOSP .301 
Giovagnoli et al. RCF: Copy <.001 Salimi et al. ACE-III Visuo-sp. .025 
Elfgren et al. Block Design .003 Park et al. E-Cog .01 




The current review demonstrates that, at a group level, individuals with Alzheimer’s Disease 
typically outperform those with Vascular Dementia, Dementia with Lewy Bodies and Posterior 
Cortical Atrophy, but perform worse than those with Frontotemporal Dementia, on tests of 
visual perception. 
 
However, although the QUADAS-2 ratings indicated few concerns regarding the clinical 
applicability of results, little is known about the diagnostic accuracy of these tests or whether 
specific cut-off scores could be used to contribute to determining dementia type. It remains 
difficult, therefore, to suggest to clinicians how results from these tests might be interpreted to 
inform decisions regarding differential diagnosis. Whilst there may be group-level differences 
in performance on tests of visual perception, there may nevertheless be considerable overlap 
between groups in distribution of test scores. Therefore, at an individual level patients with two 
different aetiologies may both score within an average range on a test. Without cut-off scores 
to indicate what level of performance might be characteristic of different dementia types, it 
may not be possible to use individual test scores for differential diagnosis. It may be more 
productive, however, to combine neuropsychological test scores from a range of domains, 
perhaps in combination with other biomarkers such as magnetic resonance imaging (MRI) or 
cerebrospinal fluid (CSF) markers to determine if the patterns of scores are more accurate in 
predicting dementia type.  One example of this approach is tested in Tolonen et al., (2018) in 
which a disease state index classifier model, utilising neuropsychological, MRI, and CSF data, 
is used to predict the likelihood of a patient falling into one of five categories:  controls with 
subjective cognitive decline; dementia due to Alzheimer’s disease; vascular dementia; 
frontotemporal lobar degeneration; dementia with Lewy bodies. 
 
In addition, the overall quality of research in this area could be improved. In particular, many 
of these studies display a high risk of bias relating to patient selection and fail to adequately 
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illustrate or report the participant’s journey (’flow’) through the study. Many studies fail to 
provide sufficient detail regarding the time interval between the index test and reference 
standard, although these items were described and reported adequately in most cases. These 
issues could be addressed by recruiting participants based on consecutive referrals, thereby 
simplifying and standardising the ‘flow’ of participants through the study and perhaps helping 
to clarify the time interval between the reference standard and index test. 
Limitations of the Review 
Although the studies included all addressed the overall review question, the review was unable 
to improve understanding of how performance on tests of visual perception vary between 
dementia types other than between Alzheimer’s Disease and various other dementias. Also, 
due to the variety of different tests and disease types, and the variation in statistical values 
reported across each study, it was not possible to conduct a meta-analysis of study results. 
It is possible that the inclusion criteria and search terms used led to the exclusion of relevant 
studies, including studies which were not published in English or included participants with 
unconfirmed diagnoses of dementia. Also, the search terms used may not have captured all 
relevant studies, however handsearching of reference lists led to only one additional study 
being identified suggesting that it is unlikely that studies were missed. 
Finally, although an independent rater was included only 10% of the potential studies identified 
by the search process were screened, and only 50% of the studies included in the review were 
independently reviewed for risk of bias. Ideally, all studies returned by the search process, 
and all studies included in the review, would have been screened and reviewed by an 
independent rater. However, although this was not possible within the scope of the current 




Areas for Future Research and Clinical Practice 
The current review highlights the importance of inclusion of tests of visual perception during 
neuropsychological assessment. This review should prompt additional research into the 
nature and extent of visual perception difficulties that are associated with different forms of 
dementia, which may lead to more accurate and timely diagnosis for those experiencing 
symptoms of dementia. More accurate identification of visual problems may also increase 
attention to interventions to manage impairments in everyday activities. This may include, for 
example, adaptations to the individual’s physical environment (improved lighting, pictorial 
signage, high contrast flooring) and regular input from occupational therapy and 
ophthalmology services, which can help limit the negative impact of visual difficulties on 
symptoms related to disorientation and confusion (Dawes et al., 2019).  
 
It may be useful for subsequent reviews to focus on visual processing in non-Alzheimer’s 
Disease dementias. This could help to provide a more comprehensive understanding of 
differential diagnosis between different dementia types. Future reviews could perhaps also 
focus on studies applying specific statistical measures of diagnostic accuracy, e.g., 
sensitivity/specificity, or specific tests of visual impairment in order for a more meaningful 




This review provides clinically relevant information relating to how visual perception is 
impacted by dementia. More specifically, the review demonstrated the differences in visual 
perception experienced by individuals with Alzheimer’s Disease and those diagnosed with 
other forms of dementia. The ACE-III, Clock Drawing Task and Pentagon Copy in particular 
appear to quickly and reliably highlight these differences. However, although significant 
differences in test performance between different groups were observed, the review was not 
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able to improve understanding of the diagnostic accuracy of these tests. It should be noted 
that many of these tests were included within brief screening batteries aimed at assessing 
various cognitive domains, and should therefore be used to prompt more detailed assessment 
of visual, and overall cognitive, impairment.  
There is a need to improve the evidence base regarding the use of tests of visual perception 
for differential diagnosis in dementia, and evaluate whether accurate cut-off scores on tests of 
visual perception can be determined. It would be interesting to investigate whether regression 
models using test results from several cognitive domains, together with biomarker measures, 
can improve diagnostic accuracy. It is essential however that any studies aiming to improve 
the evidence base in this way minimise risk of bias and maintain high methodological 
standards, perhaps via reference to and guidance by tools such as the QUADAS-2 and 
STARD guidelines.  
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PLAIN ENGLISH SUMMARY 
Title 
Diagnostic Accuracy of the Visuo-spatial domain of the Addenbrooke’s Cognitive Examination 
III 
Background 
Many people diagnosed with dementia will experience some form of visual impairment, with 
visuo-spatial function among the most common visual process affected (Geldmecher, 2003). 
Accurate measurement of visuo-spatial ability is essential therefore to inform clinical 
judgement and may also assist with differential diagnosis and management of risk. However, 
the evidence base for tests of visuo-spatial ability is relatively limited. The Addenbrooke’s 
Cognitive Examination (third edition: ACE-III; Hsieh et al, 2013) is a widely used screening 
tool for symptoms of neurocognitive decline, and although this includes a measure of visuo-
spatial ability it is unclear how accurately this detects visuo-spatial impairment in individuals 
with dementia and Mild Cognitive Impairment (MCI). 
Aims 
The study aimed to assess how well the ACE-III detects visuo-spatial deficits in individuals 
with dementia and MCI. In addition, the study aimed to identify the optimal cut-off score for 
interpretation of ACE-III visuo-spatial performance and identification of visuo-spatial 
impairment. 
What the study involved 
The electronic health records of individuals diagnosed with dementia or MCI were accessed 
in order to obtain pre-existing scores on the ACE-III visuo-spatial domain. Results from other 
detailed neuropsychological tests of visuo-spatial function were used to assign participants to 
either a visual impairment (VI) group or a no impairment (NI) group. A total of 49 people were 
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allocated to the visual impairment group while 103 people were allocated to the no impairment 




The VI group performed significantly more poorly than the NI group on the ACE-III visuo-
spatial sub-test. The ACE-III showed ‘fair’ diagnostic accuracy for detecting visuo-spatial 
impairment. The optimal cut-off score was 12.5, whereby individuals obtaining scores of 12 or 
below are likely to display visuo-spatial impairment.   
 
Conclusions 
The study demonstrated that the ACE-III is an adequate measure of visuo-spatial impairment 
in individuals with dementia and MCI. However, this should be used alongside more extensive 
neuropsychological assessment in cases where screening measures indicate the requirement 
for additional testing of dementia symptoms. 
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Background: As many as 32.5% of individuals diagnosed with dementia will experience some 
form of visual impairment (Bowen et al, 2016), with visuo-spatial function among the most 
common visual process affected (Geldmecher, 2003). Reliable assessment in this area is 
therefore essential to accurate diagnosis. The Addenbrookes Cognitive Examination (ACE-III) 
is one of the most widely used screening tools in dementia assessment and includes a set of 
tests measuring visuo-spatial ability, with a sub-scale score ranging from 0-16. Little is known 
about the test’s diagnostic accuracy in this specific cognitive domain. Aims: This study 
examined how well the ACE-III detects visuo-spatial impairment in individuals with dementia 
and Mild Cognitive Impairment (MCI).  Methods: The electronic health records of individuals 
with a pre-existing diagnosis of dementia or Mild Cognitive Impairment (MCI) were accessed 
to obtain scores on the visuo-spatial domain of the ACE-III. Individuals were included in the 
study if they had completed a battery of neuropsychological tests which included assessment 
of visuo-spatial ability. Performance on these tests were used to allocate participants to either 
a visual impairment (VI) group or no impairment (NI) group. Scores on the visuo-spatial sub-
test of the ACE-III were then examined to compare the VI and NI groups and determine the 
diagnostic accuracy of the test. Results: ACE-III visuo-spatial scores were significantly lower 
in the VI group (n=49; Mdn=12.0) than the NI group (n=103; Mdn=14.0). Receiver Operating 
Curve (ROC) analysis indicated ‘fair’ (Area Under Curve =.77) diagnostic accuracy. Scores of 
12 and below are suggested as the optimal cut-off score to indicate visuo-spatial impairment, 
offering sensitivity and specificity values of .61 and .85.  Conclusion: The visuo-spatial sub-
test of the ACE-III is an adequate measure of visual impairment in individuals with dementia 
or MCI. However, this should be administered alongside additional tests of visual impairment 
included within more detailed neuropsychological assessment if screening measures indicate 
the requirement for additional testing of dementia symptoms. 





Dementia is one of the leading threats to global health and is a major cause of disability and 
dependence among older adults (World Health Organization, 2020). Currently, the syndrome 
affects as many as 46.8 million people worldwide, however this number is expected to double 
by 2050 (Prince et al, 2015). Between 5-8% of individuals over the age of 60 are diagnosed 
with dementia (World Health Organization, 2020). Women are more likely than men to be 
diagnosed with dementia, and it is the leading cause of death for women and second leading 
cause of death for men in the United Kingdom (Prince et al, 2015). 
 
Dementia includes various symptoms which can impair a person’s abilities in several cognitive 
domains such as memory, language, attention and executing functioning (World Health 
Organization, 2018). These symptoms are impacted in different ways by different forms of the 
syndrome, the most common of which is Alzheimer’s Disease which is experienced by 
between 50-75% of dementia patients (Alzheimer’s Society, 2020). All types of dementia, and 
the associated decline in cognitive function, are progressive in nature and involve shrinkage 
of the brain caused by cellular damage.  
 
Almost one third of the neocortex is involved in visual processes (Van Essen and Drury, 1997). 
It is perhaps unsurprising therefore many individuals diagnosed with dementia experience 
some form of visual impairment (Bowen et al, 2016). Visual impairment can include deficits in 
visuo-spatial ability, defined by Simic et al. (2013) as “processes involved in perceiving spatial 
location, orientation, direction and distance” (p1119), and visuo-constructional ability, defined 
as “skills needed to put together parts to form a single whole” (Simic et al. (2013; p 1119)). 
Many tests aiming to assess visuo-spatial ability depend upon a combination of basic visual 
perception (acuity and object perception), spatial and perceptuomotor functions for successful 
performance.  Visual impairment of any sort, but including visuo-spatial ability, can increase 
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the risk of falls (Fernando et al, 2017) and reduce mobility and overall quality of life (van 
Ooteghem et al, 2019) for individuals diagnosed with dementia or Mild Cognitive Impairment 
(MCI).  
 
Accurate measurement of visuo-spatial ability is essential therefore to understand the nature 
of a person’s difficulties and may contribute to differential diagnosis and risk management. 
Although several well-validated tests are available for measuring cognitive domains such as 
memory (Wechsler, 1987), language (Savage et al, 2013) and attention (Robertson et al, 
1994) in the context of dementia, the evidence base relating to the usefulness of tests 
designed to assess visuo-spatial ability in people with dementia is relatively limited. The 
Addenbrooke’s Cognitive Examination (third edition: ACE-III; Hsieh et al, 2013) is a widely 
used screening tool for symptoms of neurocognitive decline and includes a measure of visuo-
spatial ability. However, it is unclear how accurately the visuo-spatial domain of the ACE-III 
detects visuo-spatial impairment in individuals with dementia and MCI. 
 
Aims 
This study aimed to assess how well the ACE-III detects visuo-spatial deficits in individuals 
with dementia and MCI. This was achieved by comparing the performance of individuals with 
and without visuo-spatial impairment on the visuo-spatial domain of the ACE-III. In addition, 
the study aimed to identify the optimal cut-off score for interpretation of ACE-III visuo-spatial 




Participants included people who received a diagnosis of dementia or MCI following 
neuropsychological assessment from a qualified clinical psychologist based within an NHS 
Greater Glasgow and Clyde (NHS GG&C) Older Adult Community Mental Health Team 
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(OACMHT). Participants satisfied ICD-11 (WHO, 2018) criteria for diagnosis of dementia 
(6D80-86, 6D8Y, 6D8Z) or MCI (6D71). 
Eligibility Criteria 
Inclusion Criteria 
In order to be included in the study, participants were required to have completed the ACE-III 
as part of the cognitive assessment which led to their diagnosis of dementia or MCI. In 
addition, at least one separate test of visuo-spatial ability must have been administered as 
part of a complete neuropsychological assessment. Complete neuropsychological 
assessment was operationalised as that involving an assessment battery utilising validated 
measures of cognitive domains identified in the ICD-11 (WHO, 2018) as necessary for 
assessment and diagnosis. This includes memory, executive functioning, attention, language, 
social cognition and judgement, psychomotor speed and visuo-perceptual or visuo-spatial 
ability. 
Exclusion Criteria 
Those who met the following criteria were excluded from participation in the study: 
• Individuals who had an unconfirmed or unclear diagnosis of dementia or MCI
• Individuals for whom visual impairment was unknown or unclear
• Individuals with a physical impairment which may have impacted upon motor
performance during tests of visuo-spatial ability (e.g., arthritis, Parkinson’s Disease)
• Individuals who completed the ACE-III more than six months before or after the
neuropsychological assessment




Ethical approval was granted from the West of Scotland Research Ethics Service on 5th 
November 2020 (REC Reference: 20/WS/0156; Appendix 2.4). Permission to proceed with 
the study was also provided by the local Caldicott Guardian and by the NHS GG&C Research 
and Innovation service.  
 
Research was conducted by a trainee clinical psychologist under the supervision of a qualified 
clinical psychologist. The British Psychological Society’s ‘Code of Human Research Ethics’ 
(BPS, 2014) and ‘Code of Ethics and Conduct’ (BPS, 2018) also guided the researcher’s 
practice and ensured that safe and appropriate research principles were applied throughout 
the study. Recording and electronic storage of confidential patient information adhered to the 
Data Protection Act 2018 (UK Government, 2018), the United Kingdom’s implementation of 
the General Data Protection Regulation (GDPR, 2018). 
 
Recruitment Procedures 
Following appropriate organisational and ethical approval, the lead author contacted all 
qualified clinical psychologists based across the six NHS GG&C Health and Social Care 
Partnership areas (East Dunbartonshire, East Renfrewshire, Inverclyde, Glasgow City, 
Renfrewshire, West Dunbartonshire). Clinicians were asked to provide the names and unique 
Clinical Health Index (CHI) numbers of all clients known to their service who satisfied the 
inclusion criteria and who did not violate the exclusion criteria.  
 
Using the CHI numbers, the electronic health records of these individuals were then accessed 
by the lead author via the Egton Medical Information Systems (EMIS) digital health platform. 
Following an additional check for inclusion and exclusion criteria, relevant data for each 
participant was extracted from the EMIS digital health platform and recorded in a password 




Justification of Sample Size 
Bujang and Adnan (2016) note that sensitivity is the most appropriate measure of diagnostic 
utility for screening tests (over and above specificity). They provide indicators of minimum 
sample sizes for sensitivity analysis based on prevalence of the condition of interest in the 
population being sampled, and for different levels of sensitivity. Based on an estimated 
prevalence of visual impairment in people with dementia of 30% (Bowen et al., 2016), 45 
people with visual impairment, and a total sample of 150, was proposed as a minimum sample 
size for determining the sensitivity if sensitivity is at least 0.8 (power of 0.826, p=0.0034).  
 
A sample of 45 people with impairment and 105 without would have 90% power to detect a 
difference of d=0.76 in an independent samples t-test. In order for the ACE-III to effectively 
detect differences between the visual impairment (VI) and no impairment (NI) groups, and for 
clinicians to be confident in the clinical accuracy of these results, a large (d=0.8) effect size 
for this separation would be required (p<0.05, two-tailed).  
 
Between April 2019 and March 2020, 2,187 individuals were diagnosed with dementia or MCI 
across NHS GG&C. Following discussions with members of a local OACMHT, it was estimated 
that around 3% of these individuals were likely to have undergone neuropsychological 
assessment. Therefore, approximately 66 individuals would be expected to receive a 
neuropsychological assessment per year, and around 528 in the 8 years the ACE-III has been 
used within NHS GG&C.  As such, it was expected that obtaining the required sample size 
would have been realistic within the timeline proposed.  
 
Measures 
The visuo-spatial sub-test of the ACE-III represented the dependent variable of the study. In 
this test, individuals complete five tasks which rely on visuo-spatial abilities. These include a 
clock drawing task, copying two diagrams (infinity diagram and wire cube), dot counting and 
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fragmented letter identification. Scores on each sub-test are summed to produce a sub-scale 
score that can range from 0–16. 
 
The independent variable, i.e., allocation to the VI or NI group, was determined by 
performance on visuo-spatial tests included in participant’s full neuropsychological 
assessment batteries. If performance on at least one test of visuo-spatial ability fell within the 
bottom fifth percentile (or, Z-Score <-1.67; T-Score<33; Scaled Score<5: Standard Score<75), 
participants were allocated to the VI group. Some common neuropsychological assessments 
used within NHS GG&C include, among others, the Repeatable Battery for the Assessment 
of Neuropsychological Status (RBANS; Randolph, 2012), the Mini-Mental State Exam (MMSE; 
Folstein et al, 1975) and the Severe Impairment Battery (SIB; Saxton et al, 1990), each of 
which include measures of visuo-spatial ability. 
 
Demographic factors including age and gender were also recorded, as was dementia type. 
Postcodes were used to determine socio-demographic information based on Scottish Index of 
Multiple Deprivation (SIMD) rank and decile. 
 
Design and Procedure 
A between-groups observational design was used in order to determine how accurately the 
ACE-III can identify visuo-spatial impairment. The study utilised existing data from 
neuropsychological assessments, and as such there was no requirement for face-to-face 
contact with participants or direct assessment. 
 
Once potential participants had been identified, relevant data was recorded on a password 
protected Microsoft Excel database and stored on a secure NHS file drive. An anonymised 
data set was created for analysis using study ID pseudonyms, and postcodes were removed 




The statistics package IBM® SPSS (version 27.0) was used to analyse the results of the study. 
The Shapiro-Wilk test revealed that age was normally distributed, however all other data items 
deviated from normal distribution. Appropriate non-parametric tests (Mann Whitney U-test) 
were used to examine differences between the VI and NI groups for ACE-III visuo-spatial 
score, SIMD Decile and SIMD Rank, while age was analysed using an Independent Samples 
t-test. A Chi-square test for independence was used to explore gender-based differences
between each group, and statistical values, significance level and effect sizes are presented 
for the overall sample as well as for sub-groups based on dementia type. 
Diagnostic accuracy was determined using Receiver Operating Characteristic (ROC) curve 
analysis and the Sensitivity, Specificity, Youden Index, Likelihood Ratios, Positive Predictive 
Values and Negative Predictive Values were calculated for various cut-off scores. 
RESULTS 
Preliminary Analyses 
The study included 49 participants in the visual impairment (VI) group and 103 participants in 
the no impairment (NI) group. Preliminary analyses using the Shapiro Wilks Test found that 
age was normally distributed in the VI group (W=.967, p=.182) and NI group (W=.982, p=.187). 
However, for both the VI and NI groups ACE-III Visuo-spatial scores (W=.952, p=.046; 
W=.852, p<.001), SIMD Decile (W=.848, p<.001; W=.861, p<.001) and SIMD Rank (W=.878, 
p<.001; W=.892, p<.001) significantly deviated from normal. Therefore, analyses for age were 
investigated using parametric analysis while ACE-III Visuo-spatial scores, SIMD Decile and 
SIMD Rank were analysed using non-parametric tests. 
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Demographic Characteristics and Test Performance 
Details of participant demographics and test performance for each group is outlined in Table 
7 (below). This includes information on gender and mean, median, standard deviation, 
interquartile range and range relating to age, SIMD Decile, SIMD Rank and ACE-III Visuo-
spatial scores. 


























71.7 ± 7.4 
(54-90) 
72.3 ± 8.1 
(54-90) 
71.5 ± 7.1 
(55-87) 






4.1 ± 3.1 
(1-10) 
4.5 ± 3.3 
(1-10) 
4.0 ± 2.9 
(1-10) 
z=-.53 .59 r=.04 
Median 
(IQR) 





























13.0 ± 2.8 
(3-16) 
11.1 ± 3.3 
(3-16) 
14.0 ± 2.0 
(7-16) 
z=-5.33 <.001 r=.43 
Median 
(IQR) 
14.0 (3.0) 12.0 (5.0) 14.0 (2.0) 
The majority of participants were female (N=81), however a Chi-square test for independence 
(with Yates Continuity Correction) indicated no significant association between gender and 
group membership, χ2(1, n=152)=.69, p=.41. 
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Similarly, an Independent Samples t-test found that the mean age of participants in the VI 
group (M=72.3, SD=8.1) and NI group (M=71.5, SD=7.1) did not differ significantly (t(150)=.62, 
p=.537)). SIMD Decile (Mdn=4.0, IQR=6.5) and SIMD Rank (Mdn=2495.0, IQR=4340.5) were 
higher in the VI group than in the NI group (Mdn=3.0, IQR=9.0: Mdn=1804.0, IQR=3505.0), 
but again a Mann-Whitney U Test revealed that these differences were not significant 
(U=2390.5, z=-.53, p=.59, r=.04; U=2391, z=-.52, p=.6, r=.04). 
A significant difference between the groups for ACE-III Visuo-spatial scores was detected 
(U=1188, z=-5.33, p<.001), with scores lower in the VI group (M=11.1, SD=3.3; Mdn=12.0, 
IQR=5.0) than in the NI group (M=14.0, SD=2.0; Mdn=14.0, IQR=2.0). A medium-large effect 
size (r=.43) for this difference was detected. Figure 3 highlights the percentages of each score 
recorded in each group. 




This illustrates that the majority of participants in the NI group (N=87, 84.5%) obtained a score 
of 13 or more, while the majority of participants in the VI group (N=30, 61.2%) obtained a score 
below 13.  
 
Diagnostic Utility 
Receiver Operating Characteristic (ROC) curve analysis was completed to determine the 
optimal cut-off score for the Visuo-spatial sub-test of ACE-III. Figure 4 displays the ROC curve 
for ACE-III Visuo-spatial score differentiating the VI from NI groups. The Area Under the Curve 
(AUC; .77, 95% C.I.=.68 - .85) indicated ‘fair’ diagnostic accuracy.  
 
 
Figure 4:  ROC Curve of ACE-III Visuo-spatial test detecting visual impairment 
 
In order to determine the optimal cut-off score for detecting the presence of visuo-spatial 
impairment, the sensitivity, specificity, Youden Index, Likelihood Ratios (LR+; LR-) and 
positive and negative predictive values (PPV; NPV) were obtained. These values are 
presented in Table 8.  
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Table 8: Sensitivity, Specificity, Youden Index, Likelihood Ratios (LR+; LR-) Positive Predictive 
Values (PPV) and Negative Predictive Values (NPV) for the ACE-III Visuo-spatial test at different 
cut-off scores for visual impairment 
Cut-off* Sensitivity Specificity 
Youden 
Index 
+LR -LR PPV (%) NPV (%) 
15.5 .92 .24 .16 1.21 .33 36.6 86.2 
14.5 .84 .47 .31 1.58 .34 42.7 85.7 
13.5 .74 .69 .43 2.39 .38 52.9 84.5 
12.5 .61 .85 .46 4.07 .46 65.2 82.1 
11.5 .49 .87 .36 3.77 .59 64.9 78.3 
10.5 .37 .91 .28 4.11 .69 66.7 75.2 
9.5 .31 .95 .26 6.20 .73 75.0 74.2 
8.5 .18 .98 .16 9.00 .84 81.8 71.6 
7.5 .14 .99 .13 14.00 .87 87.5 70.8 
6.5 .12 1.00 .12 ∞ .88 100 70.5 
5.5 .08 1.00 .08 ∞ .92 100 69.6 
4.5 .04 1.00 .04 ∞ .96 100 68.7 
3.5 .02 1.00 .02 ∞ .98 100 68.2 
* ACE-III scores include whole values only; decimal values used for illustration
Table 8 indicates that if one uses the maximum Youden’s J score to define the optimal cut-off, 
then an ACE-III Visuo-spatial cut-off score should be 12.5, i.e., scores of 12 and below indicate 
visual impairment and scores of 13 and above to indicate no impairment. This gives a True 
Positive Rate (TPR - Sensitivity) of 61% and a True Negative Rate (TNR - Specificity) of 85%, 
as well as Likelihood Ratios of +LR=4.07 and -LR=.46. Individuals achieving a score of 12 or 
less would have a 65.2% chance of their Visuo-spatial impairment diagnosis being correct, 
while those scoring 13 or above would have an 82.1% chance of a negative test result being 
correct. 
Disease Characteristics 
Disease specific information relating to type of dementia diagnosis in each group is outlined 
in Table 9 (below).  
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Table 9: Prevalence of dementia types in Visual Impairment (VI) group, No Impairment (NI) 
group and overall, and percentages within disease groups 
 
Dementia Type 



















13 26.5 20.3 51 49.5 79.7 64 (42.1) 
Alzheimer’s 
Disease (AD) 
14 28.6 40.0 21 20.4 60.0 35 (23.0) 
Vascular Dementia 
(VD) 
6 12.2 27.3 16 15.5 72.7 22 (14.5) 
Frontotemporal 
Dementia (FTD)* 
8 16.3 57.1 6 5.8 42.9 14 (9.2) 
Mixed: AD & VD 4 8.2 44.4 5 4.9 55.6 9 (5.9) 
Mixed: AD & FTD 2 4.1 100.0 0 0.0 0.0 2 (1.3) 




0 0.0 0.0 1 1.0 100.0 1 (0.7) 
Posterior Cortical 
Atrophy (PCA) 




1 2.0 100.0 0 0.0 0.0 1 (0.7) 
Unspecified 0 0.0 0.0 1 1.0 100.0 1 (0.7) 
*Includes those diagnosed with Behavioural Variant FTD (bvFTD) and Primary Progressive Aphasia 
(PPA) 
 
As Figure 5 highlights, the most common diagnosis overall was MCI (42.1%). This was also 
the most common diagnosis within the NI group, accounting for almost half (49.5%) of all 
diagnoses and was the second most common diagnosis within the VI group (26.5%). 
Alzheimer’s Disease was the most common diagnosis in the VI group (28.6%) and second 
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most common overall (23.0%) and in the NI group (20.4%), followed by Vascular Dementia 
which accounted for 14.5% of overall diagnoses.  
 
 
Figure 5: Percentages of dementia diagnoses within Visual Impairment group, No Impairment 
group and Total 
 
Differences within each dementia ‘type’ between the VI group and NI group were also 
analysed. Table 10 highlights the demographic and test characteristics for each dementia 
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N (%) 13 (20.3) 51 (79.7) 64 (100.0)   
Male (%) 4 (30.8) 24 (47.1) 28 (43.8) 
X2 (1, n = 64) = 
.55 
.46 
phi =  
.13 
Age 
M, +- SD, 
(Range) 










3350.0, 5074.0 (57 - 
6758) 
2485, 3433.0 (16 - 
6916) 
2485.0, 3919.5 (16 - 
6916) 





13.0, 5.0 (4 - 16) 14.0, 2.0 (9 - 16) 14.0, 2.0 (4 - 16) z = -2.07 .04 
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11.0, 3.5 (9 - 14) 14, 3.3 (7 - 16) 13.5, 3.3 (7 - 16) z = -1.88 .06 r = .40 
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As Table 10 illustrates, the only significant differences in ACE-III scores identified 
between the VI and NI groups within dementia type was in the Alzheimer’s Disease (AD) 
and Mild Cognitive Impairment (MCI) groups. Within each, those in the VI group obtained 
significantly lower scores (AD: U=56.5, z=-3.09, p=.002, r=.52; MCI: U=210.0, z=-.207, 
p=.04, r=.26), with large and small-medium effect sizes detected for these differences, 
respectively. Also, the median age of individuals diagnosed with Frontotemporal 
Dementia in the VI group was higher (Mdn=76.5, IQR=13.5) than those in the NI group 
(Mdn=67.0, IQR=9.0). This difference approached significance (U=8.5, z=-2.01, p=.05, 
r=.54) with a large effect size. 
Similarly, although medium effect sizes between the VI and NI groups were detected for 
ACE-III scores in those diagnosed with Frontotemporal Dementia (r=.44) and Vascular 
Dementia (r=.40), the samples in these disease groups were too small to obtain a 
significant value, despite a p value approaching significance (p=.06) for the latter sample. 
DISCUSSION 
The study found that, for individuals diagnosed with dementia or MCI, the ACE-III visuo-
spatial sub-test displays ‘fair’ diagnostic accuracy for differentiating between individuals 
with and without visuo-spatial impairment. Those with visuo-spatial impairment 
performed significantly worse on this test than those with no visuo-spatial impairment, 
and a medium-large effect size for the difference between these groups was identified. 
A score of 12.5 is suggested as the optimal cut-off score for classification of visuo-spatial 
/no visuo-spatial impairment. This would offer a True Positive Rate (Sensitivity) of .61 
and a True Negative Rate (Specificity) of .85, meaning that 61% of individuals with visuo-
spatial impairment would be correctly classified as such. Individuals who have no visuo-
spatial impairment would be correctly classified in 85% of cases. 
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However, it is worth considering Bujang and Adnan’s (2016) assertion that sensitivity, 
over and above specificity, is the most appropriate measure of diagnostic utility for 
screening tests. Applying a cut-off score of 13.5 would increase sensitivity to .74, 
ensuring that 74% of individuals with a visuo-spatial impairment would be correctly 
classified. However, this would also increase the false positive rate from 15% to 31%. 
Clinicians should therefore consider clinical priorities and implications when interpreting 
these scores. Applying a higher cut-off threshold would reduce the likelihood that visuo-
spatial difficulties are missed, yet this would also lead to a higher rate of false positives. 
However, these would perhaps be identified and corrected after follow-up visuo-spatial 
testing as part of more comprehensive neuropsychological assessment. This 
emphasises the importance of utilising the ACE-III as a screening tool to determine 
whether more detailed assessment is required, as opposed to its use as a standalone 
instrument for diagnosis of dementia, or in this case detection of visuo-spatial difficulties. 
The modest sensitivity highlights the importance of clinicians considering carefully the 
patient’s history and reports from patient or significant others regarding everyday 
difficulties that suggest the presence of visuo-spatial dysfunction. The presence of such 
difficulties should trigger more detailed investigation of visuo-spatial functions, even if a 
patient scores above the cut-off on the ACE visuo-spatial score. 
The study supported the finding by Bowen et al (2016) that 32.5% of individuals with 
dementia display some form of visual impairment, with 32.2% of participants being 
allocated to the VI group. No significant differences in SIMD rank or decile were identified 
between the VI and NI groups, suggesting that social deprivation is not associated with 
increased risk of visuo-spatial impairment. However, levels of deprivation were higher 
for the NI group, and this effect was also observed when analysing the Frontotemporal, 
MCI, Mixed Dementia and Vascular Dementia groups separately. Again, it may be the 
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case that the sample sizes were too small to detect significant differences in SIMD rank 
and decile values between the VI and NI groups.  
When analysing group differences based on dementia type, the VI group performed 
worse on the ACE-III visuo-spatial sub-test across all disease types. However, significant 
differences were only detected in the Alzheimer’s Disease and MCI groups. 
The most common diagnosis recorded was MCI, with 64 (42.1%) participants receiving 
this diagnosis. When analysing dementia types only, in line with prevalence rates 
reported elsewhere (Alzheimer’s Society, 2020), Alzheimer’s Disease (39.8%) and 
Vascular Dementia (25%) were the first and second most common dementia. However, 
although Dementia with Lewy Bodies and Frontotemporal Dementia are reported to 
typically affect 10-15% and 2% of dementia patients respectively, only one participant 
(1.1%) received this former diagnosis while 15.9% of participants with dementia were 
reported to have Frontotemporal Dementia. This observation is perhaps influenced by 
referral pathways within NHS GG&C, wherein patients experiencing symptoms of 
Dementia with Lewy Bodies may be more likely to be referred to neurology due to 
overlapping symptoms with Parkinson’s Disease, including problems with movement and 
visual hallucinations (Jellinger, 2018). Those with Frontotemporal dementia however 
often exhibit more behavioural features, including changes in personality and social 
interaction (Benussi et al., 2021), and are therefore more likely to be referred to 
psychology services for neuropsychological assessment. 
Strengths and Limitations 
The study successfully obtained the required sample size indicated in the power 
analysis. This included participants from a variety of socio-demographic backgrounds, 
reflected by the wide range of SIMD decile (1-10) and rank (16-6961) values. However, 
this was drawn from a predominantly urban population and included only those referred 
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to older adult psychology services. Many individuals with dementia may receive their 
diagnosis from primary care services, neurology or geriatricians, and the sample may 
therefore not be wholly representative of individuals with dementia. Also, the study 
design did not enable recording of factors such as ethnicity, disability, education, 
employment or pre-morbid mental or physical health factors. 
Also, although disease type was recorded and helped to provide some useful insight into 
how visuo-spatial impairment impacts different types of dementia, the sample sizes were 
insufficient to detect any significant disease-specific effects. As the study was 
observational in design it was not possible to include a control group. In the absence of 
COVID-19 restrictions the researcher would have been able to administer the ACE-III 
and additional neuropsychological assessment prospectively with participants and 
include a control group. This could also have enabled disease severity/stage of illness 
to have been controlled for, and data relating to age of onset could have been collected. 
In addition, a detailed and comprehensive assessment of visuo-spatial ability could have 
been used to determine the presence or absence of visuo-spatial impairment. The visuo-
spatial assessment battery proposed by de Vries et al. (2018), for example, could have 
ensured the standardisation of measures used for group allocation. 
Finally, although all measures were administered by qualified clinical psychologists, or 
by trainee clinical psychologists under the supervision of qualified clinical psychologists, 
there may be variability in how these measures were administered and interpreted. While 
the use of different examiners and assessments may have introduced extraneous 
variables into the study, using existing data perhaps reduced the risk of expectancy 
effects and demand characteristics. This may also have ensured that the results are 
more representative of, and generalisable to, clinical settings. 
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Areas for Future Research 
Future research could aim to include larger sample sizes of various dementia types in 
order to improve understanding of the diagnostic accuracy of the ACE-III visuo-spatial 
sub-test across different diseases. This research could, in addition, improve 
understanding of how visuo-spatial impairment differs between these dementia types.  
 
It may also be beneficial to examine the diagnostic accuracy of individual items within 
the ACE-III visuo-spatial sub-test. This could help to determine whether the overall 
accuracy could be improved by, for example, improving any tasks which fail to 
significantly differentiate between visually impaired and non-visually impaired groups, or 
whether individuals with particular diagnoses frequently display floor or ceiling effects on 
particular items.  
 
Finally, replication of this study using prospective data and inclusion of a control group 
may enable researchers to capture more accurate information relating to ethnicity, 
disability, education, employment and pre-morbid mental or physical health factors. This 
could, for example, improve understanding of how different dementia types impact 
individuals from Black, Asian and Minority Ethnic (BAME) backgrounds and whether 
wider societal and health inequalities influence referrals and patient demographics 
observed within public health services.  
 
CONCLUSION 
The study provides evidence that the ACE-III Visuo-spatial domain detects the presence 
of visuo-spatial impairment with fair accuracy at a cut-off of 12.5. However, clinicians 
must also pay close attention to patient history, and to contemporary accounts and 
observations regarding everyday visuo-spatial functions, in order to determine if more 
detailed investigation of visuo-spatial ability are required. These findings should be of 
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benefit to clinicians by improving the accuracy of neuropsychological assessment, which 
in turn should help to ensure individuals experiencing cognitive decline receive timely 
and definitive diagnosis. 
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(iv) Each author should have participated sufficiently in the work to take
public responsibility for appropriate portions of the content. 
Authors should meet the conditions of all of the points above. When a large, 
multicentre group has conducted the work, the group should identify the 
individuals who accept direct responsibility for the manuscript. These individuals 
should fully meet the criteria for authorship. 
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Acquisition of funding, collection of data, or general supervision of the research 
group alone does not constitute authorship, although all contributors who do not 
meet the criteria for authorship should be listed in the Acknowledgments 
section. Please refer to the International Committee of Medical Journal Editors 
(ICMJE) authorship guidelines for more information on authorship. 
2.3 Acknowledgements 
All contributors who do not meet the criteria for authorship should be listed in an 
Acknowledgements section. Examples of those who might be acknowledged 
include a person who provided purely technical help, or a department chair who 
provided only general support. 
Any acknowledgements should appear first at the end of your article prior to 
your Declaration of Conflicting Interests (if applicable), any notes and your 
References. 
2.3.1 Third party submissions 
Where an individual who is not listed as an author submits a manuscript on behalf of 
the author(s), a statement must be included in the Acknowledgements section of the 
manuscript and in the accompanying cover letter. The statements must: 
• Disclose this type of editorial assistance – including the individual’s name,
company and level of input
• Identify any entities that paid for this assistance
• Confirm that the listed authors have authorized the submission of their
manuscript via third party and approved any statements or declarations, e.g.
conflicting interests, funding, etc.
Where appropriate, SAGE reserves the right to deny consideration to manuscripts 
submitted by a third party rather than by the authors themselves. 
2.3.2 Writing assistance 
Individuals who provided writing assistance, e.g. from a specialist 
communications company, do not qualify as authors and so should be included 
in the Acknowledgements section. Authors must disclose any writing assistance 
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– including the individual’s name, company and level of input – and identify the
entity that paid for this assistance. It is not necessary to disclose use of 
language polishing services. 
2.4 Funding 
Journal of Geriatric Psychiatry and Neurology requires all authors to 
acknowledge their funding in a consistent fashion under a separate heading. 
Please visit the Funding Acknowledgements page on the SAGE Journal Author 
Gateway to confirm the format of the acknowledgment text in the event of 
funding, or state that: This research received no specific grant from any funding 
agency in the public, commercial, or not-for-profit sectors. 
2.5 Declaration of conflicting interests 
It is the policy of Journal of Geriatric Psychiatry and Neurology to require a 
declaration of conflicting interests from all authors enabling a statement to be 
carried within the paginated pages of all published articles. 
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included 
at the end of your manuscript, after any acknowledgements and prior to the 
references. If no conflict exists, please state that ‘The Author(s) declare(s) that 
there is no conflict of interest’. For guidance on conflict of interest statements, 
please see the ICMJE recommendations here 
2.6 Research ethics and patient consent 
Medical research involving human subjects must be conducted according to 
the World Medical Association Declaration of Helsinki 
Submitted manuscripts should conform to the ICMJE Recommendations for the 
Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical 
Journals, and all papers reporting animal and/or human studies must state in 
the methods section that the relevant Ethics Committee or Institutional Review 
Board provided (or waived) approval. Please ensure that you have provided the 
full name and institution of the review committee, in addition to the approval 
number. 
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For research articles, authors are also required to state in the methods section 
whether participants provided informed consent and whether the consent was 
written or verbal. 
Information on informed consent to report individual cases or case series should 
be included in the manuscript text. A statement is required regarding whether 
written informed consent for patient information and images to be published was 
provided by the patient(s) or a legally authorized representative. Please do not 
submit the patient’s actual written informed consent with your article, as this in 
itself breaches the patient’s confidentiality. The Journal requests that you 
confirm to us, in writing, that you have obtained written informed consent but the 
written consent itself should be held by the authors/investigators themselves, for 
example in a patient’s hospital record. The confirmatory letter may be uploaded 
with your submission as a separate file. 
Please also refer to the ICMJE Recommendations for the Protection of 
Research Participants 
All research involving animals submitted for publication must be approved by an 
ethics committee with oversight of the facility in which the studies were 
conducted. The journal has adopted the Consensus Author Guidelines on 
Animal Ethics and Welfare for Veterinary Journals published by the International 
Association of Veterinary Editors. 
2.7 Clinical trials 
Journal of Geriatric Psychiatry and Neurology conforms to the ICMJE 
requirement that clinical trials are registered in a WHO-approved public trials 
registry at or before the time of first patient enrolment as a condition of 
consideration for publication. The trial registry name and URL, and registration 
number must be included at the end of the abstract. 
2.8 Reporting guidelines 
The relevant EQUATOR Network reporting guidelines should be followed 
depending on the type of study. For example, all randomized controlled trials 
submitted for publication should include a completed CONSORT flow chart as a 
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cited figure and the completed CONSORT checklist should be uploaded with 
your submission as a supplementary file. Systematic reviews and meta-
analyses should include the completed PRISMA flow chart as a cited figure and 
the completed PRISMA checklist should be uploaded with your submission as a 
supplementary file. The EQUATOR wizard can help you identify the appropriate 
guideline. 
Other resources can be found at NLM’s Research Reporting Guidelines and 
Initiatives 
2.9. Research Data 
The journal is committed to facilitating openness, transparency and 
reproducibility of research, and has the following research data sharing 
policy. For more information, including FAQs please visit the SAGE Research 
Data policy pages. 
Subject to appropriate ethical and legal considerations, authors are encouraged 
to: 
• share your research data in a relevant public data repository
• include a data availability statement linking to your data. If it is not possible to
share your data, we encourage you to consider using the statement to explain
why it cannot be shared.
• cite this data in your research
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1 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1.9 
2 2 2 2 1 1 1 2 2 1 2 2 1 1 2 1.6 
3 2 2 1 1 2 2 1 2 1 2 1 1 1 1 1.4 
4 2 2 2 1 2 2 2 1 1 1 1 1 1 1 1.4 
5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2.0 
6 1 2 2 1 1 1 2 2 2 1 1 1 1 2 1.4 
7 1 2 2 2 1 2 2 2 2 1 1 1 1 2 1.6 
8 1 1 1 1 1 1 2 1 2 1 1 1 1 1 1.1 
9 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2.0 
10a 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2.0 
10b 2 2 2 2 2 2 2 2 2 2 2 1 2 2 1.9 
11 2 2 1 1 2 1 1 1 1 1 1 0 2 1 1.2 
12a 0 0 0 0 1 0 1 1 0 1 1 1 1 0 0.5 
12b 2 1 2 2 2 2 1 1 1 1 2 1 2 2 1.6 
13a 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 
13b 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 
14 2 2 2 2 1 2 2 2 1 2 1 2 1 2 1.7 
15 0 0 0 0 1 0 1 1 0 1 0 0 0 1 0.4 
16 0 1 1 0 2 0 0 0 0 1 0 0 0 0 0.4 
17 0 0 1 1 1 1 1 1 1 2 0 0 0 1 0.7 
18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 
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19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 
20 2 2 2 2 1 2 1 1 2 1 2 2 1 2 1.6 
21a 1 1 2 2 2 2 1 1 1 1 0 0 1 1 1.1 
21b 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0.1 
22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 
23 2 2 2 2 2 2 2 2 2 2 1 1 2 2 1.9 
24 2 2 2 2 2 1 1 1 2 2 1 2 1 1 1.6 
25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 
26 1 1 2 1 1 0 1 1 2 2 1 0 2 1 1.1 
27 2 1 1 1 1 1 1 1 2 2 1 1 1 2 1.3 
Total/62 35 35 38 33 37 33 34 34 34 36 28 25 30 36 33.4 
92 
MAJOR RESEARCH PROJECT APPENDICES (CHAPTER 2) 
Appendix 2.1 – Manuscript Submission Guidelines: Journal of Geriatric 
Psychiatry and Neurology (Sections 1 and 2: Full submission guidelines 
available at https://journals.sagepub.com/author-instructions/JGP) 
Manuscript Submission Guidelines: 
Manuscript Submission Guidelines: Journal of Geriatric Psychiatry and 
Neurology 
This Journal is a member of the Committee on Publication Ethics 
This Journal recommends that authors follow the Recommendations for the 
Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical 
Journals formulated by the International Committee of Medical Journal Editors 
(ICMJE). 
Please read the guidelines below then visit the Journal’s submission 
site https://mc.manuscriptcentral.com/jgpn to upload your manuscript. 
Please note that manuscripts not conforming to these guidelines may be 
returned. Remember you can log in to the submission site at any time to 
check on the progress of your paper through the peer review process. 
Only manuscripts of sufficient quality that meet the aims and scope of Journal of 
Geriatric Psychiatry and Neurology will be reviewed. 
There are no fees payable to submit or publish in this journal. 
As part of the submission process you will be required to warrant that you are 
submitting your original work, that you have the rights in the work, and that you 
have obtained and can supply all necessary permissions for the reproduction of 
any copyright works not owned by you, that you are submitting the work for first 
publication in the Journal and that it is not being considered for publication 
elsewhere and has not already been published elsewhere. Please see our 
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guidelines on prior publication and note that Journal of Geriatric Psychiatry 
and Neurology may accept submissions of papers that have been posted 
on pre-print servers; please alert the Editorial Office when submitting (contact 
details are at the end of these guidelines) and include the DOI for the preprint in 
the designated field in the manuscript submission system. Authors should not 
post an updated version of their paper on the preprint server while it is being 
peer reviewed for possible publication in the journal. If the article is accepted for 
publication, the author may re-use their work according to the journal's author 
archiving policy. If your paper is accepted, you must include a link on your 
preprint to the final version of your paper. 
1. What do we publish?
1.1 Aims & Scope 
1.2 General Instructions 
1.3 Writing your paper 
2. Editorial policies




2.5 Declaration of conflicting interests 
2.6 Research ethics and patient consent 
2.7 Clinical trials 
2.8 Reporting guidelines 
2.9 Research Data 
3. Publishing policies
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3.1 Publication ethics 
3.2 Contributor’s publishing agreement 
3.3 Open access and author archiving 
3.4 Plain language summaries 
4. Preparing your manuscript
4.1 Formatting 
4.2 Artwork, figures and other graphics 
4.3 Supplemental material 
4.4 Reference style 
4.5 English language editing services 
5. Submitting your manuscript
5.1 ORCID 
5.2 Information required for completing your submission 
5.3 Permissions 
6. On acceptance and publication
6.1 SAGE Production 
6.2 Online First publication 
6.3 Access to your published article 
6.4 Promoting your article 
7. Further information
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1. What do we publish?
1.1 Aims & Scope 
Before submitting your manuscript to Journal of Geriatric Psychiatry and 
Neurology, please ensure you have read the Aims & Scope. 
1.2 General Instructions 
Manuscripts should be submitted electronically 
to https://mc.manuscriptcentral.com/jgpn. Authors will be required to set up an 
online account on the SageTrack system powered by ScholarOne. Manuscripts 
will be sent out anonymously for editorial evaluation. Obtaining permission for 
any quoted or reprinted material that requires permission is the responsibility of 
the author. Submission of a manuscript implies commitment to publish in the 
journal. Authors submitting manuscripts to the journal should not simultaneously 
submit them to another journal, nor should manuscripts have been published 
elsewhere in substantially similar form or with substantially similar content. 
Authors in doubt about what constitutes prior publication should consult the 
Editor: James M. Ellison, MD, MPH, James.M.Ellison@ChristianaCare.org. 
Authors should keep for their own files a copy of all works submitted. 
Submission of a manuscript to the Journal of Geriatric Psychiatry and 
Neurology is taken as evidence that no portion of the text or figures have been 
copyrighted, published, or submitted for publication elsewhere unless 
information regarding previous publication is explicitly cited and permission 
obtained (a copy of such permission must be provided with the manuscript). 
All material (abstracts, keywords, text, tables, and figure captions) should be 
typed double-spaced. Computer preparation is mandatory. Subheading should 
be used to designate the different sections of the text. References should be 
numbered consecutively throughout the text. Provide a list of three to six 
keywords to assist indexing of the article. 
Articles of any length are considered. 
Title page: The title should be brief and meaningful. The authors’ first and last 
names, academic or medical degrees, and affiliations should follow the title. 
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Authorship should be limited to direct participants, although technical assistance 
can be acknowledged as a footnote. A separate paragraph should identify 
where the work was done, if supported by a grant or otherwise, and the 
meeting, if any, at which the paper was presented. 
Abstract: An abstract of approximately 150 words should be provided on. This 
abstract should be factual and should present the reason for the study, the main 
findings, and the principal conclusions. 
Text: This should follow the usual format for scientific articles. Pages should be 
numbered consecutively. All abbreviations should be spelled out at first 
mention. Only generic names of drugs should be used. 
Figures and tables: Special care should be given to the preparation of figures 
and tables, including captions and explanatory information. Technical 
excellence is stressed. Lettering and arrows, where applicable, should be done 
in a professional manner. Color illustrations are unacceptable for publication 
without prior permission of the publisher. Recognizable photographs of patients 
must be masked and must carry with them written permission for publication. 
Captions for all figures should be typewritten double-spaced, with numbers 
corresponding to those on the figures themselves. 
Tables should be numbered consecutively according to their in-text citation. 
Each should be typed double-spaced and should be no larger than a single 
page. Include a brief descriptive title and an indication of its position in the text. 
References: Authors are responsible for correctness and completeness of 
references. References should be typed double-spaced on separate pages. 
They should be arranged according to their order of appearance in the text, and 
indicated by superscript numbers. References should be typed in accordance 
with the style shown below for book and journal articles. Up to four authors 
should be listed; when there are more than four, only the first three should be 
listed, followed by "et al." Abbreviations of journal names should conform to the 
style in Index Medicus. Abstracts, editorials, and letters to the editor should be 
noted as such. Personal communications, unpublished manuscripts submitted 
but not yet accepted, and similar unpublished items should not appear in the 
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reference list. Such citations may be noted in the text. Some basic information 
regarding references and the reference list has been listed below. 
References List 
Basic rules for the reference list: 
• The title “References” is centered at the top of a separate page at the end of the
document.
• Entries are preceded by their number and are given in numerical order.
• The reference list should be single-spaced. Single-space between entries.
• The second line and all subsequent lines of each item in the reference list
should be indented (hanging indent).
• Do not use “et al.” in the Reference list at the end; names of all authors of a
publication should be listed there.
Here are a few examples of commonly found references. For more examples 
please check AMA (11th Ed). 
• Books Author(s) separated by commas.
o Title of Book. Place of publication: Publisher; year.
o Goldberg L, Elliot DL. Exercise for Prevention and Treatment of Illness.
Philadelphia, Pa: FA Davis Co; 1994.
• Edited book.
o Author(s), eds. Title of Book. Place of publication: Publisher; year.
o Armitage JO, Antman KH, eds. High Dose Cancer Therapy:
Pharmacology, Hematopoietins, Stem Cells. Baltimore, Md: Williams &
Wilkins; 1995.
• Chapter or article from a book Author(s) of article.
o Title of article. In: Editor's name, ed. Title of Book. Place of
publication: Publisher; Year: Chapter or page number.
o Gamble VN. On becoming a physician: a dream not deferred. In: White
EC, ed. The Black Women's Health Book: Speaking for Ourselves.
Seattle, Wash: Seal Press; 1990:52-64.
• Articles in journals
o AMA style requires the use of standard abbreviations for all references,
when applicable. Abbreviations for many common medical journals can
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be found in the AMA Manual of Style (pp.473-479). Additional 
abbreviations can be searched in the PubMed Journal Database 
(http://www.ncbi.nlm.nih.gov/nlmcatalog/journalbs). 
• One author (do not include issue number or month unless volumes are not
consecutively numbered)
o Author. Article title. Journal Title. Month Year;Volume:Inclusive page
numbers.
o Angelo J. A survey of persons who use integrated control
devices. Assist Technol. 1998;10:77-83.
• Articles in Online Journals
o The preferred citation style for an electronic journal uses a DOI (digital
object identifier). The DOI provides a persistent link to the electronic
item and is considered to be more stable than a URL. If the DOI is not
given on the full text article or in the citation, use a DOI lookup tool to
locate it (http://www.crossref.org/guestquery/) or use the format for an
article without a DOI.
• Article from online journals with DOI available. Note that when using a DOI,
no access date or URL are used.
o Author. Title of article. Name of Journal. Year;vol(issue):pages.
doi:xx.xxxx.
o Florez HR, Martinez RL. Outdoor exercise reduces the risk of
hypovitaminosis D in the obese. J Steroid Biochem Mol Bio. 2007;103(3-
5):679-681. doi:10.1016 /j.jsbmb.2006.12.032.
• Article from online journals without DOI available. The accessed date will
often be the only date available.
o Author. Title of article. Name of Journal. Year;vol(issue);pages.
URL. Published date. Updated date. Accessed date.
o Hay PJ. Understanding bulimia. Aust Fam Physician. 2007;36(9):708-
712. http://www.racgp.org.au/afp/200709/18554. Accessed October 11,
2009. 
• Web pages
o Author or responsible body. Title of item cited. Name of website.
URL. Published date. Updated date. Accessed date.




ml. Published July 7, 2007. Accessed October 11, 2009.
• Other Media. Use for DVDs, videos, cd-roms, and other media formats.
o Author. Title [format]. Publisher place: Publisher; Year.
o Holzknect J. History of physical therapy in the United States [DVD]. New
York, NY: Insight Media; 2007.
IMPORTANT NOTE: To encourage a faster production process of your article, 
you are requested to closely adhere to the points above for references. 
Otherwise, it will entail a long process of solving copyeditor’s queries and may 
directly affect the publication time of your article. In case of any question, please 
contact the journal editor at James.M.Ellison@ChristianaCare.org. 
1.3 Writing your paper 
The SAGE Author Gateway has some general advice and on how to get 
published, plus links to further resources. 
1.3.1 Make your article discoverable 
For information and guidance on how to make your article more discoverable, 
visit our Gateway page on How to Help Readers Find Your Article Online 
2. Editorial policies
2.1 Peer review policy 
Journal of Geriatric Psychiatry and Neurology operates a conventional single-
blind reviewing policy in which the reviewer’s name is always concealed from 
the submitting author. 
Journal of Geriatric Psychiatry and Neurology is committed to delivering high 
quality, fast peer-review for your paper, and as such has partnered with 
Publons. Publons is a third party service that seeks to track, verify and give 
credit for peer review. Reviewers for JGP and can opt in to Publons in order to 
claim their reviews or have them automatically verified and added to their 
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reviewer profile. Reviewers claiming credit for their review will be associated 
with the relevant journal, but the article name, reviewer’s decision and the 
content of their review is not published on the site. For more information visit 
the Publons website. 
The Editor or members of the Editorial Board may occasionally submit their own 
manuscripts for possible publication in the journal. In these cases, the peer 
review process will be managed by alternative members of the Board and the 
submitting Editor/Board member will have no involvement in the decision-
making process. 
2.2 Authorship 
Papers should only be submitted for consideration once consent is given by all 
contributing authors. Those submitting papers should carefully check that all 
those whose work contributed to the paper are acknowledged as contributing 
authors. 
The list of authors should include all those who can legitimately claim 
authorship. This is all those who: 
(i) Made a substantial contribution to the concept or design of the work; or
acquisition, analysis or interpretation of data, 
(ii) Drafted the article or revised it critically for important intellectual
content, 
(iii) Approved the version to be published,
(iv) Each author should have participated sufficiently in the work to take
public responsibility for appropriate portions of the content. 
Authors should meet the conditions of all of the points above. When a large, 
multicentre group has conducted the work, the group should identify the 
individuals who accept direct responsibility for the manuscript. These individuals 
should fully meet the criteria for authorship. 
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Acquisition of funding, collection of data, or general supervision of the research 
group alone does not constitute authorship, although all contributors who do not 
meet the criteria for authorship should be listed in the Acknowledgments 
section. Please refer to the International Committee of Medical Journal Editors 
(ICMJE) authorship guidelines for more information on authorship. 
2.3 Acknowledgements 
All contributors who do not meet the criteria for authorship should be listed in an 
Acknowledgements section. Examples of those who might be acknowledged 
include a person who provided purely technical help, or a department chair who 
provided only general support. 
Any acknowledgements should appear first at the end of your article prior to 
your Declaration of Conflicting Interests (if applicable), any notes and your 
References. 
2.3.1 Third party submissions 
Where an individual who is not listed as an author submits a manuscript on behalf of 
the author(s), a statement must be included in the Acknowledgements section of the 
manuscript and in the accompanying cover letter. The statements must: 
• Disclose this type of editorial assistance – including the individual’s name,
company and level of input
• Identify any entities that paid for this assistance
• Confirm that the listed authors have authorized the submission of their
manuscript via third party and approved any statements or declarations, e.g.
conflicting interests, funding, etc.
Where appropriate, SAGE reserves the right to deny consideration to manuscripts 
submitted by a third party rather than by the authors themselves. 
2.3.2 Writing assistance 
Individuals who provided writing assistance, e.g. from a specialist 
communications company, do not qualify as authors and so should be included 
in the Acknowledgements section. Authors must disclose any writing assistance 
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– including the individual’s name, company and level of input – and identify the
entity that paid for this assistance. It is not necessary to disclose use of 
language polishing services. 
2.4 Funding 
Journal of Geriatric Psychiatry and Neurology requires all authors to 
acknowledge their funding in a consistent fashion under a separate heading. 
Please visit the Funding Acknowledgements page on the SAGE Journal Author 
Gateway to confirm the format of the acknowledgment text in the event of 
funding, or state that: This research received no specific grant from any funding 
agency in the public, commercial, or not-for-profit sectors. 
2.5 Declaration of conflicting interests 
It is the policy of Journal of Geriatric Psychiatry and Neurology to require a 
declaration of conflicting interests from all authors enabling a statement to be 
carried within the paginated pages of all published articles. 
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included 
at the end of your manuscript, after any acknowledgements and prior to the 
references. If no conflict exists, please state that ‘The Author(s) declare(s) that 
there is no conflict of interest’. For guidance on conflict of interest statements, 
please see the ICMJE recommendations here 
2.6 Research ethics and patient consent 
Medical research involving human subjects must be conducted according to 
the World Medical Association Declaration of Helsinki 
Submitted manuscripts should conform to the ICMJE Recommendations for the 
Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical 
Journals, and all papers reporting animal and/or human studies must state in 
the methods section that the relevant Ethics Committee or Institutional Review 
Board provided (or waived) approval. Please ensure that you have provided the 
full name and institution of the review committee, in addition to the approval 
number. 
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For research articles, authors are also required to state in the methods section 
whether participants provided informed consent and whether the consent was 
written or verbal. 
Information on informed consent to report individual cases or case series should 
be included in the manuscript text. A statement is required regarding whether 
written informed consent for patient information and images to be published was 
provided by the patient(s) or a legally authorized representative. Please do not 
submit the patient’s actual written informed consent with your article, as this in 
itself breaches the patient’s confidentiality. The Journal requests that you 
confirm to us, in writing, that you have obtained written informed consent but the 
written consent itself should be held by the authors/investigators themselves, for 
example in a patient’s hospital record. The confirmatory letter may be uploaded 
with your submission as a separate file. 
Please also refer to the ICMJE Recommendations for the Protection of 
Research Participants 
All research involving animals submitted for publication must be approved by an 
ethics committee with oversight of the facility in which the studies were 
conducted. The journal has adopted the Consensus Author Guidelines on 
Animal Ethics and Welfare for Veterinary Journals published by the International 
Association of Veterinary Editors. 
2.7 Clinical trials 
Journal of Geriatric Psychiatry and Neurology conforms to the ICMJE 
requirement that clinical trials are registered in a WHO-approved public trials 
registry at or before the time of first patient enrolment as a condition of 
consideration for publication. The trial registry name and URL, and registration 
number must be included at the end of the abstract. 
2.8 Reporting guidelines 
The relevant EQUATOR Network reporting guidelines should be followed 
depending on the type of study. For example, all randomized controlled trials 
submitted for publication should include a completed CONSORT flow chart as a 
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cited figure and the completed CONSORT checklist should be uploaded with 
your submission as a supplementary file. Systematic reviews and meta-
analyses should include the completed PRISMA flow chart as a cited figure and 
the completed PRISMA checklist should be uploaded with your submission as a 
supplementary file. The EQUATOR wizard can help you identify the appropriate 
guideline. 
Other resources can be found at NLM’s Research Reporting Guidelines and 
Initiatives 
2.9. Research Data 
The journal is committed to facilitating openness, transparency and 
reproducibility of research, and has the following research data sharing 
policy. For more information, including FAQs please visit the SAGE Research 
Data policy pages. 
Subject to appropriate ethical and legal considerations, authors are encouraged 
to: 
• share your research data in a relevant public data repository
• include a data availability statement linking to your data. If it is not possible to
share your data, we encourage you to consider using the statement to explain
why it cannot be shared.
• cite this data in your research
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Appendix 2.2 – Template for email to NHS GG&C Older People’s Psychology 
Service Clinical Psychologists 
TO: [CLINICAL PSYCHOLOGIST] 
CC: JON EVANS; STEPHANIE CRAWFORD; 
TITLE: MRP PROJECT – [CMHT/AREA] 
Hi [CLINICAL PSYCHOLOGIST] 
I am a third year Older Adult aligned DClinPsy trainee, and I am writing to request your 
assistance in identifying potential participants for my MRP. 
My project (‘Visual Perceptual Assessment in Dementia’) aims to assess the sensitivity and 
specificity of the visuo-spatial sub-test of the ACE-III at detecting visual impairment in people 
diagnosed with dementia or MCI.  
The project will be supervised by Professor Jonathan Evans and Dr Stephanie Crawford, and 
has received approval from the West of Scotland Research Ethics Committee and the NHS 
GG&C Caldicott Guardian.  
As face to face data collection is no longer feasible for this project, I intend to utilise only 
existing data from individuals who have undergone neuropsychological assessment (including 
ACE-III) and who went on to receive a diagnosis of dementia or MCI.  
Following discussion with the supervisors and Information Services, it has been agreed that the 
most appropriate method to identify potential participants would be to individually contact 
Clinical Psychologists based within each NHS GG&C Older Adult CMHT to request this.  
I would be grateful therefore if you could populate the attached Word document with the 
names and CHI numbers of individuals who satisfy, and do not violate, the following inclusion 
and exclusion criteria: 
Inclusion Criteria: 
• Diagnosis of dementia or Mild Cognitive Impairment
• Above diagnosis given following neuropsychological assessment (which includes ACE-III
and at least one additional neuropsychological assessment measure)
Exclusion Criteria: 
• ACE-III and neuropsychological assessment completed more than 6 months
apart
• Diagnosis of a learning disability
• Physical impairment which may significantly impact motor performance (e.g.
during writing tasks in visuo-spatial sub-test of ACE-III)
When complete, the attached Word template can be saved as an attachment and returned to 
this email address (kevin.murray@ggc.scot.nhs.uk).  
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Any records dating back to 2012 could potentially be included (assuming that the ACE-III has 
not been used in your service prior to this date), however I would be extremely grateful for as 
many or as few records as you can provide.  
This is based on the assumption that most services maintain a local record (e.g. 
spreadsheet/word document) of individuals who have been assessed for dementia/MCI, and 
that the information requested could be quickly provided. However if this is not the case, or if 
this information is not easily obtainable, please let me know so that I can monitor the 
feasability of the project.   
Thank you for any help you can provide. 
Regards, 
Kevin Murray 
Trainee Clinical Psychologist 
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Appendix 2.3 – Data Collection template for email to NHS GG&C Older People’s 
Psychology Service Clinical Psychologists 
Data Collection Template 
Visual Perceptual Assessment in Dementia 
Please use this form to record the names and CHI numbers of potential participants for 
the ‘Visual Perceptual Assessment in Dementia’ study. This form should be returned to: 
kevin.murray@ggc.scot.nhs.uk 
First Name Surname CHI Number 
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Appendix 2.5 – NHS GG&C Board Approval Letter 
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Appendix 2.6 – NHS GG&C Caldicott Guardian Approval Letter 
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Appendix 2.7 – Study Protocol 
RESEARCH STUDY PROTOCOL 
TITLE  
Visual Perceptual Assessment in Dementia 
INTRODUCTION 
Rationale  
Although several well-validated tests are available for measuring common symptoms of 
dementia and Mild Cognitive Impairment (MCI) such as memory, language, executive 
function and attention, the methods available for assessing visuo-perceptual ability are 
relatively limited. The Addenbrooke’s Cognitive Examination (Third edition: ACE-III; 
Hsieh at al., 2013) is a widely used cognitive screening tool, and although this includes 
a measure of visuo-spatial ability it is unclear how accurately this detects visual 
perceptual deficits in individuals with dementia and MCI. 
Background information including literature review 
Almost one third of the neocortex is involved in visual processes (Van Essen and Drury, 
1997). It is perhaps unsurprising therefore that as many as 32.5% of individuals 
diagnosed with dementia experience visuo-perceptual decline as part of their disease 
aetiology (Bowen et al, 2016), with incidence rates highest in those diagnosed with 
Alzheimer’s Dementia (Alzheimer’s Society, 2018). Impairment in visual processing is 
associated with an increased risk of falls for those diagnosed with dementia (Fernando 
et al, 2017) and can reduce mobility (van Ooteghem et al, 2019). Accurate measurement 
of visuo-perceptual ability is therefore essential to informing clinical decisions, and may 
also assist with differential diagnosis and risk management. 
Potential risk and benefits 
This study aims to assess the accuracy of the ACE-III at detecting visuo-perceptual 
deficits in individuals with dementia and MCI, thereby improving understanding of the 
methods available for informing clinical judgement. In doing so it is hoped that the overall 
accuracy of dementia diagnosis, including differential diagnosis, will be enhanced. As 
there will be no direct contact with participants, and existing data will be used for analysis, 
there are no risks to participants anticipated. 
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AIM/PRIMARY AND SECONDARY OBJECTIVES 
This study aims to assess how well the ACE-III detects visuo-perceptual deficits in 
individuals with dementia or MCI. This will be achieved by comparing the performance 
of individuals with and without visuo-perceptual impairment on the visuospatial sub-test 
of the ACE-III. The current study therefore will test the hypothesis that individuals with 
visual impairment will obtain significantly lower scores on the visuo-perceptual sub-test 
of the ACE-III than individuals with no visual impairment. 
METHODOLOGY 
Inclusion and Exclusion Criteria 
Participants will include clients who have been under the care of NHS Greater Glasgow 
and Clyde Older Adult Community Mental Health Teams (CMHTs).  In order to be 
included in the study participants are required to have completed the ACE-III and a 
separate visuo-spatial sub-test as part of their neuropsychological assessment, and 
have a diagnosis of dementia or mild cognitive impairment (MCI). 
Those who meet the following criteria will be excluded from participation in the study: 
• Individuals for whom visual-perceptual impairment is unknown or unclear
• ACE-III and neuropsychological assessment completed more than 6 months
apart
• Diagnosis of a learning disability
• Physical impairment which may impact motor performance e.g. during writing
tasks in visuo-spatial sub-test of ACE-III
Study design / Plan – Study Visits 
A between-groups observational design will be utilised in order to determine how 
accurately the ACE-III can identify visual perceptual impairment. The study will utilise 
existing data from neuropsychological assessments, and there will be no requirement for 
face to face contact with participants or direct assessment. 
Research will be conducted by a trainee clinical psychologist, who will be supervised 
throughout the project by a qualified clinical psychologist to ensure safe and appropriate 
research principles are followed. The British Psychological Society’s ‘Code of Human 
Research Ethics’ (BPS, 2014) and ‘Code of Ethics and Conduct’ (BPS, 2018) will also 
guide the researcher’s practice, and local ethical and Caldicott Guardian approval will be 
sought to ensure appropriate research standards are maintained. 
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Once potential participants have been identified, the relevant data will be recorded on a 
password protected Microsoft Excel database on an NHS computer. An anonymised 
data set will be created for analysis using study ID numbers and transferred to a 
university network file via email from a secure NHS email account, and postcodes will be 
removed and replaced with relevant SIMD ranking. CHI numbers will also be removed, 
and no personally identifiable data will be transferred out-with an NHS computer. 
The visuo-spatial sub-test of the ACE-III represents the dependent variable of the study. 
In this sub-test, individuals complete five tasks which rely on visuo-spatial abilities. These 
include drawing an analogue clock, copying two diagrams (infinity diagram and wire 
cube), dot counting and fragmented letter identification. Scores on this measure, which 
can range from 0 – 16, will be used to assess the sensitivity and specificity of the ACE-
III at detecting visual impairment in dementia. 
The independent variable, i.e. allocation to the impaired or unimpaired group, will be 
determined by performance on visual perceptual sub-tests included in participant’s full 
neuropsychological assessment batteries. Participants will be considered impaired if 
their visual perceptual performance falls in the bottom 5th percentile (or, Z-Score <-1.67; 
T-Score<33; Scaled Score<5: Standard Score<75). The most commonly used
neuropsychological assessments which involve tests of visual perceptual impairment 
include the Repeatable Battery for the Assessment of Neuropsychological Status 
(RBANS), Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV), Severe 
Impairment Battery (SIB) and Kaplan Baycrest Neurocognitive Assessment (KBNA). 
Demographic factors including age and gender will be recorded. Postcode will also be 
recorded in order to determine Scottish Index of Multiple Deprivation (SIMD) rank. 
Disease-specific factors (i.e. diagnosis) will also be recorded. 
Durations of participation 
There will be no face to face contact with participants, and only existing data from 
participant’s health records will be used for the study. Therefore, participants are not 






Criteria for discontinuation 
Not applicable 
Procedure for collecting data and storage 
A trainee clinical psychologist (‘researcher’) will be responsible for collecting and 
analysing the data. Following approval from the local ethics committee and Caldicott 
Guardian, clinical psychologists based within OACMHTs across the eight NHS GG&C 
Health and Social Care Partnerships (East Dunbartonshire, East Renfrewshire, 
Inverclyde, Glasgow North East, Glasgow North West, Glasgow South, Renfrewshire, 
West Dunbartonshire) will be contacted individually by the trainee to request details of 
clients within their service who satisfy the inclusion criteria, and who do not violate the 
exclusion criteria. 
The health records of these individuals will then be accessed by the researcher, and 
following an additional check for inclusion and exclusion criteria the details of those 
appropriate for the study will be added to a password protected Microsoft Excel database 
on an NHS laptop computer. The list of potential participants in the database will then be 
randomised using the ‘Randomise’ function within Microsoft Excel, and the first 150 
individuals on this list will be included in the study. 
STATISTICAL CONSIDERATIONS 
Sample Size 
Bujang and Adnan (2016) note that sensitivity is the most appropriate measure of 
diagnostic utility for screening tests (over and above specificity). They provide indicators 
of minimum sample sizes for sensitivity analysis based on prevalence of the condition of 
interest in the population being sampled, and for different levels of sensitivity. Based on 
an estimated prevalence of visual impairment in people with dementia of 30% (Brown et 
al., 2016), 45 people with visual impairment, and a total sample of 150, is proposed as a 




A sample of 45 people with impairment and 105 without would have 90% power to detect 
a difference of d=0.76 in an independent samples t-test. In order for the ACE-III to 
effectively detect differences between the impaired and unimpaired groups, and for 
clinicians to be confident in the clinical accuracy of these results, a large (d=0.8) effect 
size for this separation would be required (p<0.05, two-tailed).  
 
Between April 2019 and March 2020, 2,187 individuals were diagnosed with dementia 
or MCI across NHS GG&C. Following discussions with members of a local OACMHT, it 
is estimated that around 3% of these individuals are likely to have underwent 
neuropsychological assessment. Therefore, approximately 66 individuals would be 
expected to receive a neuropsychological assessment per year, and around 528 in the 
8 years the ACE-III has been used within NHS GG&C.  As such, it is expected that 
obtaining the required sample size is realistic within the timeline proposed.  
 
Method of Analysis  
The statistics package SPSS will be used to analyse the results of the study, and data 
will initially be checked for normality, skew and kurtosis. If the data are normally 
distributed, or is non-normally distributed but can be transformed to satisfy the 
requirements for parametric testing, an independent samples t-test will be used to 
compare the mean ACE-III scores between the impaired and unimpaired groups. 
 
If the data is not normally distributed and transformation for parametric testing is not 
possible, then a Mann-Whitney test will be used to compare the medians of each group. 
The sensitivity and specificity of the ACE-III visuo-perceptual sub-test will be investigated 
using Receiver Operating Characteristic (ROC) curve analysis. Descriptive statistics will 




The study will utilise existing data only and there is no requirement for face to face 
contact with the researcher. However, approval from the NHS ethics committee will be 
sought, as well as approval to access and use patient information from the NHS GG&C 
Caldicott Guardian and from the Research and Innovation service. 
 
Collection, storage and dissemination of data will adhere to the appropriate guidelines 
stipulated by the Data Protection Act 2018 (UK Government, 2018), in particular 
schedule 19 within Chapter 2 (‘Processing for archiving, research and statistical 
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purposes: safeguards’). The Research Governance Framework for Health and 
Community Care (NHS GG&C, 2006) will also be followed to ensure the study upholds 
the ethical standards required. 
FINANCE AND INDEMNITY 
The University of Glasgow Doctorate in Clinical Psychology programme student 
research budget will cover any research costs incurred.  
Indemnity will also be provided under the University of Glasgow’s ‘Legal Liability and No 
Fault Compensation for Human Clinical Trials’ insurance policy.  
PUBLICATIONS 
It is intended that the completed study will be published in a peer reviewed scientific 
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Up to 32.5% of individuals diagnosed with dementia experience visuo-perceptual 
decline. Accurate assessment in this area is essential therefore. The Addenbrookes 
Cognitive Examination (ACE-III) is one of the most widely used screening tools in 
dementia assessment, and contains a measure of visuo-spatial ability. Little is known 
about the test’s diagnostic accuracy in this area however. 
Aims 
The current study aims to assess how well the ACE-III can detect visuo-perceptual 
impairment in individuals with neurocognitive decline. 
Methods 
Individuals with dementia or mild cognitive impairment (MCI) will complete a Visual 
Assessment Battery (VAB) and will be allocated to either a visually impaired or visually 
unimpaired group, based on these results. They will also complete the visuo-spatial sub-
test of the ACE-III. Scores on the visuo-spatial sub-test of the ACE-III will then be 
analysed to compare the impaired and unimpaired groups and to determine the test’s 
sensitivity and specificity to visuospatial impairment. 
Applications 
The results of the study will help towards understanding of the diagnostic validity of the 
ACE-III, and if necessary alternative methods for assessment of visuo-spatial ability in 
individuals with dementia or MCI will be proposed. 
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1. INTRODUCTION
Almost one third of the neocortex is involved in visual processes (Van Essen and Drury, 
1997). It is perhaps unsurprising therefore that as many as 32.5% of individuals 
diagnosed with dementia experience visuo-perceptual decline as part of their disease 
aetiology (Bowen et al, 2016), with incidence rates highest in those diagnosed with 
Alzheimer’s Dementia (Alzheimer’s Society, 2018). Impairment in visual processing is 
associated with an increased risk of falls for those diagnosed with dementia (Fernando 
et al, 2017) and can reduce mobility (van Ooteghem et al, 2019). Accurate measurement 
of visuo-perceptual ability is therefore essential to informing clinical decisions, and may 
also assist with differential diagnosis and risk management. 
Although several well-validated tests are available for measuring common symptoms of 
dementia such as memory, language, executive function and attention, the methods 
available for assessing visuo-perceptual ability are relatively limited. The Addenbrooke’s 
Cognitive Examination (Third edition: ACE-III; Hsieh at al., 2013) is a widely used 
cognitive screening tool, and although this includes a measure of visuo-spatial ability it 
is unclear how accurately this detects visuo-perceptual deficits in individuals with 
dementia. 
2. AIMS AND HYPOTHESIS
2.1 Aims
This study aims to assess how well the ACE-III detects visuo-perceptual deficits in 
individuals with dementia or Mild Cognitive Impairment. This will be achieved by 
comparing the performance of individuals with and without visuo-perceptual impairment 
on the visuospatial sub-test of the ACE-III. 
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2.2 Hypothesis 
The ACE-III aims to detect visuo-perceptual impairment in individuals with dementia. 
Therefore, the current study will test the hypothesis that individuals with visual 
impairment will obtain significantly lower scores on the visuo-perceptual sub-test of the 
ACE-III than individuals with no visual impairment. 
3. PLAN OF INVESTIGATION
3.1 Participants
Participants will include clients who have been under the care of NHS Greater Glasgow 
and Clyde Older Adult Community Mental Health Teams (CMHTs). 
3.2 Inclusion Criteria 
In order to be included in the study participants are required to have a diagnosis of 
dementia or mild cognitive impairment (MCI). This will be confirmed using the ‘diagnosis’ 
tab within the online ‘Clinical Portal’ recording system. 
3.3 Exclusion Criteria 
Those who meet the following criteria will be excluded from participation in the study: 
• Deemed to lack capacity to give informed consent
• Diagnosis of a learning disability
• Registered as blind or having a severe visual impairment
• Deaf or severe hearing impairment
• Non-fluent  English speakers
• Any other factors that would prevent the individual from fully completing the
assessment process
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3.4 Recruitment Procedures 
Individuals who satisfy the inclusion criteria, and are not disqualified by the exclusion 
criteria, will be offered an information Sheet and Cover Letter outlining the nature of the 
study by a member of their local CMHT. The contact details of those who express an 
interest in taking part will then be forwarded to the researcher, who will get in touch with 
the individual via their preferred contact method to clarify any additional questions and 
organise a testing appointment. This will take place either at the patient’s home or in their 
local CMHT clinic. 
Once written consent has been obtained the visuo-spatial sub-test of the ACE-III will be 
administered, followed by De Vries at al’s (2017) Visual Assessment Battery (VAB). If 
the participant has completed the ACE-III within the last three months however this will 
not need to be repeated. Rather, their visuo-spatial scores will be checked and re-
calculated using their existing ACE-III record form. 
3.5 Measures 
The visuo-spatial sub-test of the ACE-III represents the dependent variable of the study. 
In this sub-test, individuals complete five tasks which rely on visuo-spatial abilities. These 
include drawing an analogue clock, copying two diagrams (infinity diagram and wire 
cube), dot counting and fragmented letter identification. Scores on this measure, which 
can range from 0 – 16, will be used to assess the sensitivity and specificity of the ACE-
III at detecting visual impairment in dementia. 
The independent variable, i.e. allocation to the impaired or unimpaired group, will be 
determined by de Vries et al’s (2017) Visual Assessment Battery (VAB) which includes 
the following tests: 
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Table 1 – De Vries et al (2017); Visual Assessment Battery (VAB) 
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Demographic factors, including age, gender and socio-economic status of participants, 
will be recorded. Disease-specific factors will also be analysed and will include dementia 
type, age of onset and illness duration. 
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3.5.1 Bells Cancellation Test – Lateralised Attentional Disorders 
The Bells Cancellation Test (Gauthier et al, 1989) is a test of visual attention and is used 
to detect lateralised attentional disorders (e.g. unilateral neglect). Two-week test-retest 
reliability was reported as r=0.69 (Gauthier et al, 1989), and Ferber and Karnath (2001) 
found that the test successfully detected visual neglect in 94% of cases. Individuals are 
presented with a landscape oriented A4 sheet of paper which contains pictures of 35 
‘target’ objects (i.e. bells) and 264 ‘distracters’ (e.g. bird, key, apple, mushroom). The 
target objects, i.e. bells, are distributed evenly across the page.  Following a practice trial 
the individual is asked to circle all the bells on the page using a pencil. If six or more bells 
are omitted from the left or right half of the sheet, then the individual is considered to 
display visual neglect. 
3.5.2 Dot Counting Task (VOSP) – Non-Lateralised Attentional Disorders 
The Dot Counting Task within the Visual Object and Space Perception Battery (VOSP; 
Warrington and James, 1991) includes ten white cards with randomly arranged black 
dots. Participants are asked to identify how many dots are displayed on each card. Any 
score below the maximum is considered to indicate impairment in object and space 
perception. The Dot Counting Task was found to have low internal consistency (<0.59; 
Bonello et al, 1997), however more research is required to determine its validity and test-
retest reliability (Strauss et al, 2006). Specificity was measured as 92.8 based on the cut 
off scores provided within the manual (Bonello et al, 1997). 
3.5.3 Complex Picture Description Task (BDAE-3) – Simultanagnosia 
The Complex (‘Cookie Theft’) Picture Description task is included as a measure of 
aphasia within the Boston Diagnostic Aphasia Examination (Third edition, BDAE-3; 
Goodglass et al, 2000). De Vries et al (2017) recommended its inclusion in their Visual 
Assessment Battery as a means of assessing participant’s abilities to perceive more than 
one object at a time (i.e., to detect the presence of simultanagnosia). 
131 
Individuals are asked to describe a scene involving a black and white illustration of a boy 
is falling from a stool as he reaches for cookies, while a woman is washing dishes next 
to an overflowing sink. Individuals with simultanagnosia are likely to adopt a piecemeal 
approach to describing the image and will typically report objects in isolation (e.g. “boy”, 
“cookie”, “stool”, “dishes”) rather than describing the overall scene.. Scores up to a 
maximum of 11 are given depending on length of description, accuracy, and content, 
with 7 or below said to indicate potential simultanagnosia. 
3.5.4 Trail Making Test (D-KEFS) – Temporal Processing Disorders 
The Trail Making Test is from the Delis-Kaplan Executive Function System (D-KEFS). 
Participants complete five short tasks which rely on visual scanning strategies to identify 
and connect numbers and letters. Raw scores for each of the five conditions are 
determined by the total time to complete each task. Raw scores are then converted to 
scaled scores, with scaled scores of 6 or below suggestive of a impairment. 
3.5.5 Figure Ground Segmentation (L-Post) – Perceptual Organisation Disorders 
In the Figure Ground Segmentation sub-test of the Leuven Perceptual Organization 
Screening Test (L-Post), participants are shown a target image and three additional 
images, and are asked to identify which of the three additional images are most similar 
to the target image. This is repeated over five trials, and scores of 4 or less out of 5 are 
considered to reflect a perceptual organisation disorder.  
3.5.6 Silhouettes (VOSP) – Object Agnosia 
The Silhouettes sub-test of the Visual Object and Space Recognition Battery (VOSP) 
requires participants to identify 30 silhouetted drawings (15 animals, then 15 common 
objects) which have been rotated laterally to various angles such that these are viewed 
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from unusual angles. The test is discontinued after 5 failures in either set, and individuals 
with right hemisphere lesions identify on average 18/30 silhouettes, compared with 23/30 
for controls. 
3.5.7 Crowding Task (CORVIST) – Reduced Visual Loading (in time and space) 
The Crowding Task within the CORVIST aims to detect impairments in visual 
acuity/loading, wherein individuals struggle to identify individual visual stimuli when they 
are accompanied by other objects. Participants are shown an A4 page, at a distance of 
four metere, displaying four sets of seven numbers and letters (similar to U.K. car 
registration plates). The spacing of the numbers and letters in the upper two sets are 
visible for those with 20/40 visual acuity. The lower two sets are spaced further apart, 
such that ‘crowding’ effects do not impact on performance. Individuals who are unable 
identify all numbers and letters in the upper two sets, therefore, are considered to exhibit 
impairment in visual loading. 
3.5.8 Spatial Span (WMS-III) – Spatial (Working) Memory Disorders 
The Spatial Span sub-test of the WMS-III is an adaptation of the Corsi Block-tapping test 
(Milner, 1971). Ten blocks are arranged on a board, which examiners tap in pre-
determined orders. Examinees are asked to repeat examiner’s sequences over several 
trails, initially in the same order then in reverse order. The test is considered to be a 
visually based version of the digit span task, and is used to detect disorders in spatial 
working memory. 
3.5.9 Taylor Complex Figure (RBANS) – Visual Constructive Disorders 
The Taylor Complex Figure Test is included within the RBANS. Individuals are shown a 
complex figure and asked to copy this. Scores out of 20 are offered based on the 
accuracy and detail of the representation, which is then converted into a scaled score. 
Low scores on this task is indicative of visual constructive difficulty. 
133 
3.5.10 Global Motion Detection (L-Post) – Disorders in Movement Perception 
The Global Motion Detection sub-test of the L-Post is used to detect disorders in 
movement perception. As with the Figure Ground Segmentation sub-test, participants 
are asked to identify which of three images most closely resemble a target image. This 
is repeated five times. The images in the Global Motion Detection test include elements 
which move vertically and horizontally across the image. Scores of 3 or less out of 5 
indicate a movement perception disorder. 
3.5.11 Shape Ratio Discrimination (L-Post) – Visual Form Agnosia 
The Shape Ratio Discrimination sub-test of the L-Post is similar to the other L-Post sub-
tests wherein five trials are completed during which the participant is asked to identify 
which of three shapes most closely resemble a target image. The images in this sub-test 
include vertical lines of varying lengths and thickness, and scores of 4 or less out of 5 
indicate visual form agnosia. 
3.6 Design 
A between-groups observational design will be utilised in order to determine whether 
identification of visual impairment by the ACE-III aligns with that identified by the VAB. 
If visual impairment is not identified by any of the VAB tests then participants will be 
placed in the unimpaired group, whereas failure on one or more of the VAB tests will 
result in allocation to the impaired group. The results obtained by each group will then 
be used to determine the sensitivity and specificity of the ACE-III visuo-perceptual sub-
test. 
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3.7 Research Procedures 
The time taken to collect data from each participant is not expected to exceed one hour. 
This estimate includes time for breaks between sub-tests in the event of participant 
fatigue. 
Research will be conducted by a Trainee Clinical Psychologist, who will be supervised 
throughout the project by a qualified Clinical Psychologist to ensure safe and appropriate 
research principles are followed. The British Psychological Society’s ‘Code of Human 
Research Ethics’ (BPS, 2014) and ‘Code of Ethics and Conduct’ (BPS, 2018) will also 
guide the researcher’s practice, and local R&D and Research Ethics Committee approval 
will be sought to ensure appropriate research standards are maintained. 
3.8 Data Analysis 
The statistics package SPSS will be used to analyse the results of the study, and data 
will initially be checked for normality, skew and kurtosis. If the data are normally 
distributed, or is non-normally distributed but can be transformed to satisfy the 
requirements for parametric testing, an independent samples t-test will be used to 
compare the mean ACE-III scores between the impaired and unimpaired groups. 
If the data is not normally distributed and transformation for parametric testing is not 
possible, then a Mann-Whitney test will be used to compare the medians of each group. 
The sensitivity and specificity of the ACE-III visuo-perceptual sub-test will be investigated 
using Receiver Operating Characteristic (ROC) curve analysis. Descriptive statistics will 
include appropriate parametric or non-parametric measures of dispersion and central 
tendency. 
3.9 Justification of Sample Size 
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Bujang and Adnan (2016) note that sensitivity is the most appropriate measure of 
diagnostic utility for screening tests (over and above specificity). They provide indicators 
of minimum sample sizes for sensitivity analysis based on prevalence of the condition of 
interest in the population being sampled, and for different levels of sensitivity. Based on 
an estimated prevalence of visual impairment in people with dementia of 30% (Brown et 
al., 2016), 20 people with visual impairment, and a total sample of 67, is proposed as a 
minimum sample size for determining the sensitivity if sensitivity is at least 0.8 (power of 
0.804, p=0.041). 
A sample of 20 people with impairment and 47 without would have 90% power to detect 
a difference of d=0.76 in an independent samples t-test. In order for the ACE-III to 
effectively detect differences between the impaired and unimpaired groups, and for 
clinicians to be confident in the clinical accuracy of these results, a large (d=0.8) effect 
size for this separation would be required (p<0.05, two-tailed). 
As participants will be recruited from the various Older Adult Community Mental Health 
Teams (OACMHTs) across NHS GG&C, and considering that neurocognitive decline is 
one of the most common reasons for referral to these teams, it is expected that the 
required sample size will be obtained within the timeline proposed. 
3.10 Settings and Equipment 
Data collection will take place either in clinical rooms within Older Adult CMHT clinics or 
at participant’s homes. For administration of the assessment measures a black biro pen, 
and paper copies of the ACE-III and each of the VAB tests, will be required. Original 
copies of these, as well as the Information Sheet and signed Consent Forms, will be 
stored in a locked filing cabinet by the researcher. Copies of each will also be made 
available for storage in the participant’s clinical health file. 
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For participants who have completed the ACE-III within three months of participation in 
the study, the researcher will review and score the original ACE-III record form from their 
clinical health file (or from a scanned copy in their electronic ‘EMIS’ health record). A 
copy will also be printed and stored in a locked filing cabinet alongside the research data. 
A password protected laptop and an encrypted password protected USB memory stick 
will be used to store data electronically. 
4. HEALTH AND SAFETY ISSUES
4.1 Researcher Safety Issues
The researcher will adhere to NHS guidelines regarding lone working, health and safety 
and fire safety. For visits to participant’s homes, the researcher will ensure they have 
completed NHS GG&C’s ‘Violence Reduction’ training. 
4.2 Participant Safety Issues 
The researcher will remain mindful of the potential distress associated with 
neuropsychological assessment, and will provide regular reassurance and cease testing 
if the participant becomes distressed. 
5. ETHICAL ISSUES
Collection, storage and dissemination of data will adhere to the appropriate guidelines 
stipulated by the Data Protection Act 2018 (UK Government, 2018), in particular 
schedule 19 within Chapter 2 (‘Processing for archiving, research and statistical 
purposes: safeguards’). The Research Governance Framework for Health and 
Community Care (NHS GG&C, 2006) will also be followed to ensure the study upholds 
the ethical standards required. 
Although participants will have a confirmed diagnosis of dementia or MCI, the exclusion 
criteria will ensure that all those included in the study will retain capacity to give informed 
consent to participate in the study. Given the memory impairments inherent within this 
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population group however regular reminders of their right to withdraw will be provided 
throughout the assessment process. Other functional and cognitive impairments, 
including disorientation, attention, praxis and side effects of medication, will also be 
considered to ensure that any stressors are avoided. 
Participants who do not have visuo-perceptual deficits recorded in their clinical notes, 
but who display visual impairment in the assessment measures, will be asked if they 
wish for this information to be communicated to the clinical team within the relevant 
CMHT. This will enable the clinical team to offer appropriate advice and support, or to 
refer the individual for further visual assessment. 
6. FINANCIAL ISSUES
The University of Glasgow student research budget will cover the cost of printing 
Information Sheets, Cover Letters, Consent forms and the assessment measures. No 
other significant costs are anticipated. 
7. TIMETABLE
The project is due to be completed by July 2021. A Viva voce exam will then take place 
in September 2021, with any final corrections to be made by the following month. The 
proposed timeline of the project is outlined in Table 2: 
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Table 2 – Proposed project timeline 
2019 






October (2nd Year) 
November 
December Proposal (for blind review: 3000 words) 
2020 
January 
February Proposal feedback 
March Proposal amendments 
April Letter from Research Director 
May Submit for sponsor approval 
June Submit for ethics/R&D application 
July Data Collection 
August Data Collection 
September Data Collection 
October (3rd Year) Data Collection 
November Data Collection 
December Data Collection 
2021 
January Data Collection 
February Data Collection 
March Data Collection 
April Analysis 
May Write up 
June Write up 
July Submission 
August Draft for publication 




This study will assess the accuracy of the ACE-III at detecting visuospatial deficits in 
individuals with dementia and MCI, thereby improving understanding of the methods 
available for informing clinical judgement. In doing so it is hoped that the overall accuracy 
of dementia diagnosis, including differential diagnosis, will be enhanced. 
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10. APPENDICES
APPENDIX 1 – HEALTH AND SAFETY FORM 
WEST OF SCOTLAND/ UNIVERSITY OF GLASGOW 
DOCTORATE IN CLINICAL PSYCHOLOGY 
HEALTH AND SAFETY FOR RESEARCHERS 
1. Title of Project Visual Perceptual Assessment in Dementia 
2. Trainee Kevin Murray 
3. University Supervisor Professor Jon Evans 
4. Other Supervisor(s) Dr Stephanie Crawford, Dr Claire McGuire 
5. Local Lead Clinician Dr Stephanie Crawford 
6. Participants:  (age,  group or
sub-group, pre- or post-
treatment, etc)
Adults with diagnosis of Dementia or Mild 
Cognitive Impairment. 
7. Procedures to be applied
(eg, questionnaire, interview, etc) 
Cognitive Assessment Tests: 
Bell’s Cancellation Test (Kaplan Baycrest 
Neurocognitive Assessment),  
Dot Counting Task (Visual Object and 
Space Perception (VOSP) battery),  
Cookie Theft Picture (Boston Diagnostic 
Aphasia Examination 3 (BDAE-3)), 
Trail Making Test (Delis Kaplin Executive 
Function System (DKEFS) battery), 
Figure Ground Segmentation (Leuven 
perceptual organization screening test (L-
post)), Silhouettes (Visual Object and 
Space Perception Battery (VOSP)), 
Crowding Task (Cortical Vision Screening 
Test (CORVIST)), Spatial Span 
(Wechsler Memory Scale Third 
Edition (WMS-III)), Taylor Complex Figure 
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(The Repeatable Battery for the 
Assessment of Neuropsychological Status 
(RBANS)), Global Motion Detection (L-
Post battery), Shape Ratio Discrimination 
(L-Post battery) 
8. Setting (where will procedures
be carried out?) 
i) General
Clinical interview rooms within NHS Greater 
Glasgow and Clyde CMHT clinical bases 
Care homes/clients homes/day centres (where 
participant’s access to above settings is not 
possible) 
ii) Are home visits involved Yes (dependant on participant’s ability to 
attend settings, as detailed above) 
9. Potential Risk Factors
Considered  (for researcher 




i) It is expected that the majority of
participants will be elderly and will experience
cognitive and physical impairments.
Associated risks (including relating to mobility,
risk of falls, vulnerability) will therefore be
considered and where attendance at clinical
settings may pose a risk to participants
home/day centre visits will be offered.
ii) Potential distress resulting from the
assessment process will also be considered,
and if distress is noted participants will be
reassured and reminded that they may
withdraw at any time.
iii) Where possible, data collection will take
place within a clinical setting. Where home
visits are required however the researcher will
ensure that they have completed the
appropriate NHS GG&C ‘Violence Reduction’
and ‘Reducing Risks of Violence and
Aggression’ training and that they adhere to
the NHS GG&C Lone Working policy.
Trainee signature: Kevin Murray ............................................... Date:19/12/19 .........  
University supervisor signature:  .......................... Date:19/12/19 .........  
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APPENDIX 2 – RESEARCH EQUIPMENT, CONSUMABLES AND EXPENSES FORM 
RESEARCH EQUIPMENT, CONSUMABLES AND EXPENSES 
Trainee 
Kevin Murray………………………………………………………………………….........…… 
Year of Course  ……………2nd …………………. Intake Year………2018…….....…….. 
Please refer to latest stationary costs list (available from student support team) 
Item 
Details and Amount 
Required 
Cost or Specify if to 
Request to Borrow from 
Department 
Stationary £0 Subtotal: £0 
Postage £0 Subtotal: £0 
Photocopying and Laser 
Printing 
Participant information 
sheet (1 single sided page 
x 67; 67 x 1 x £0.05 = 
£3.35) 
Consent forms (1 single 
sided sheet x 67; 67 x 1 x 
£0.05 = £3.35) 
ACE-III (3 double sided 
sheets x 67; 67 x 3 x £0.07 
= £14.07) 
Bell’s Cancellation Test (2 
double sided sheets x 67; 
67 x 2 x £0.07 = £9.38) 
Subtotal: £30.15 
Equipment and Software £0 Subtotal: £0 
Measures 






Motion Detection; Shape 
Ratio Discrimination 
(Leuven perceptual 
* Free to access and use
online
** To be borrowed from 
Department of Clinical 
Psychology, University of 
Glasgow 
*** To be borrowed from 
West Dunbartonshire 
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organization screening test 
(L-post))*  
Dot Counting Task; 
Silhouettes 
(Visual Object and Space 
Perception (VOSP) 
battery)**  
Trail Making Test (Delis 
Kaplin Executive Function 
System (DKEFS) 
battery)** 
Crowding Task (Cortical 
Vision Screening Test 
(CORVIST))** 
Spatial Span (Wechsler 
Memory Scale Third 
Edition (WMS-III))**  
Taylor Complex Figure 
(The Repeatable Battery 
for the Assessment of 
Neuropsychological Status 
(RBANS))** 
Cookie Theft Picture 
(Boston Diagnostic 
Aphasia Examination 3 
(BDAE-3))***  
Older Adults CMHT, NHS 
GG&C 
Miscellaneous £0 Subtotal: £0 
Total £30.15 £30.15 
For any request over £200 please provide further justification for all items that contribute 
to a high total cost estimate. Please also provide justification if costing for an 
honorarium: 
Trainee Signature……Kevin Murray…………………....… Date…05/03/2020…………… 
Supervisor’s Signature …………………….......………...... Date …………...................…… 
